

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER

27656/38053

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/019098

INTERNATIONAL APPLICATION NO.

PCT/IB99/01166

INTERNATIONAL FILING DATE

22 June 1999

PRIORITY DATE CLAIMED

NONE

TITLE OF INVENTION

IN VIVO INSECT MODEL SYSTEM FOR TYPE-2 DIABETES

APPLICANT(S) FOR DO/EO/US

HAFEN, Ernst

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A copy of the International Search Report (PCT/ISA/210).

## Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Corrected International Preliminary Examination Report; Sequence Listing in paper form; Sequence Statement pursuant to 37 C.F.R. 1.821-1.825; and Return receipt post card.

U.S. APPLICATION NO. <b>10/019098</b>		INTERNATIONAL APPLICATION NO. <b>PCT/IB99/01166</b>		ATTORNEY'S DOCKET NUMBER <b>27656/38053</b>	
---------------------------------------	--	--	--	--	--

24. The following fees are submitted: <b>BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :</b>				CALCULATIONS PTO USE ONLY	
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$1040.00</b>					
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$890.00</b>					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$740.00</b>					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$710.00</b>					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100.00</b>					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$890.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				<b>\$0.00</b>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	34 - 20 =	14	x \$18.00	<b>\$252.00</b>	
Independent claims	3 - 3 =	0	x \$84.00	<b>\$0.00</b>	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$1,142.00</b>	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				<b>\$0.00</b>	
<b>SUBTOTAL =</b>				<b>\$1,142.00</b>	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				<b>\$0.00</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$1,142.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$1,142.00</b>	
				Amount to be: refunded	\$
				charged	\$

a. ☒ A check in the amount of **\$1,142.00** to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **13-2855** A duplicate copy of this sheet is enclosed.


d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jeffrey S. Sharp Customer No.: 04743 <b>MARSHALL, GERSTEIN &amp; BORUN</b> 6300 Sears Tower 233 South Wacker Drive Chicago, Illinois 60606 United States of America	<div style="text-align: center;">           SIGNATURE       </div> <div style="text-align: center;"> <b>Jeffrey S. Sharp</b>          NAME       </div> <div style="text-align: center;"> <b>31,879</b>          REGISTRATION NUMBER       </div> <div style="text-align: center;"> <b>20 December 2001</b>          DATE       </div>
---	--

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: HAFEN, Ernst )  
U.S. National Phase of PCT/IB99/01166 filed )  
22 June 1999 )  
Filed: Herewith )  
For: **IN VIVO INSECT MODEL SYSTEM** )  
**FOR TYPE-2 DIABETES** )  
Group Art Unit: Unassigned )  
Examiner: Unassigned )  
Attorney Docket No. 27656/35053 )  
I hereby certify that this paper is being de-  
posited with the United States Postal Ser-  
vice on **December 20, 2001**, in an envelope  
addressed to the Commissioner for Patents,  
Washington, D.C. 20231 utilizing the "Ex-  
press Mail Post Office to Addressee" ser-  
vice of the United States Postal Service un-  
der Mailing Label No. **EK 657 819 788 US.**  
December 20, 2001  
  
Richard Zimmermann

STATEMENT UNDER 37 C.F.R. §§1.821(f)

BOX PCT  
Commissioner for Patents  
Washington, DC 20231


Sir:

I hereby state that the content of the paper and computer readable copies of the  
Sequence Listing, submitted herewith in accordance with 37 C.F.R. §§1.821 and 1.825, are  
the same.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

By

  
Jeffrey S. Sharp  
Registration No. 31,879  
Attorney for Applicants

December 20, 2001

SEQUENCE LISTING

<110> HAFEN, Ernst

<120> In vivo model system for type-2 diabetes

<130> 27656/38053

<140> To be determined

<141> To be determined

<150> PCT/IB99/01166

<151> 1999-06-22

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 2907

<212> DNA

<213> Drosophila melanogaster

<400> 1

atggcatcaa tatcggatga cggcatggcg ctgagtggct acctcaagaa gctgaagacc 60  
atgaagaaga agttctttgt gctgtacgag gagacgagca cttcggcagc ccggctggag 120  
tactacgata ccgaaaagaa gttcctgcaa agagccgagc caaaaagggt tatatatctg 180  
aagaattgct tcaacatcaa tcgccgtttg gacaccaagc atagatttgt cattgtgctc 240  
tcctccagag acggtggatt cggcatcggt ctcgagaacg aaaatgattt acgcaaatgg 300  
ttggacaaac tactagtctt acaaaggaac atagccaatt cgaatggaac agcgcaactca 360  
ccttatgacc acgtttggca agttgtcatt caaaagaagg gtatttcgga gaaagttgga 420  
atcacccgaa cctaccactg ttgccttact tcaaaatccc tgacattcgt gtgcattgga 480  
ccggagaaga cgcccaatgg cgaggatcgc gttgagagca ttgaaatact tttgaccacg 540  
atcaggcgat gcggtcatgc atccccacaa tgtatattct acgtggaact tggccgcaa 600  
agtgtcttgg gatctggtga tctgtggatg gagacggata acgcagctat tgctactaat 660  
atgcacaaca cgatactgag cgctatgtca gccaaaacag agtcgaacac gaatttaata 720  
aacgtttatc agaatagacc tgacttaagt cacgagccca tgagaaagcg atcgtcgtct 780  
gcaaacgaag catcgaagcc gataaacgta aatgtcatac aaaatagtca aaactctctc 840  
gaattgcgca gctgcagttc gcccataac tatggtttcg gcagagagag atgcgatagc 900  
ttaccaacca gaaatggaac cctaagcgag tccagcaatc aaacgtactt tggttccaac 960  
catggactgc gatccaatac tatatctggc atcgtccgc actcaaccaa caagcatagt 1020  
aatagtccaa cgttcaccat gccattaaga tgctcagaat ccgaagagtc atcaattagt 1080  
gtcgatgaat ccgacgacaa cggcagtttt agccactaca gattaaacac gcggtcatct 1140



gagacggcaa ttcttgagga aaacattgat gactttgccg gtgcggaatt atttagcaaa 1200  
 gtcaccgaac aaaatgtaag tgacgaaaac tacataccga tgaatccagt caatcctacc 1260  
 gatgctatcc atgaaaagga gaaggctgat atgcagagat tggaagatgc ttcgctgcat 1320  
 ttcaactttc cggagcacgc gtcggaaaag cttgctaagg attttgatct ggactctgat 1380  
 aaccaatget gtcgtcccat tcgcgcctat tcgataggca acaagggtga gcattttaaag 1440  
 ttttaataagc gcctgggaca cttgaatgat acgggacaga atccgaatcg cgtgcgagcc 1500  
 tactcggttg gtcctaaatc gaagataccg cgctgcgacc tgcagcgagt ggtcctcgtg 1560  
 gaggacaata aacatgagtt cacagcgaat aggagtcaga gtagcattac caaggaagga 1620  
 accagctatg gcagcagtcg caatcgacaa aagaagtcca caagtgcctc actcctcagt 1680  
 ctgaagaacc agataaaactc cgaccgaatg agtgacttaa tggaaattga tttttcacia 1740  
 gcaaccaatt tggaaaagca gaagttcatc aagaataatg aaattccgaa atacattgaa 1800  
 aacgtgttcc caaaagcccc gcgaacggat agctccagcc taactctgca cgccacaagt 1860  
 caaaaggaca ttttcaatgg caccaaacta aataaactg cgatcacatc cgaggatggt 1920  
 tacctcgaga tgaagccagt cggtaatgga tacactcca gttcgaattg cctgccaatg 1980  
 aaagtggaga aactcaagct atccgactat cagacagcac cgccactcac cgcaacagcc 2040  
 gcaccagtgc acgattttaa caaaattagc acatacaata tatccgctga gaaatggaga 2100  
 gaacagccca gcagaagcga ggaaaagaag tcgaactcgc cattgaatga caacaccttt 2160  
 agctcgaaac ccacaaatgt cgagagtaca agcaaaagcc atgatgttca ttcagcaaat 2220  
 caaattgatt gcgagaaagt gtgcgcgcag agcagcgata agctaaataa tcatctggcc 2280  
 gacaagattg tcgagaacaa caatttggat ataggcgggc atgaggaaaa gaagttggtt 2340  
 cattcgataa gcagcgaaga ctacacacaa atcaaggaca aatcgaatga tttcacaaaa 2400  
 tttaacgaag ccggctacaa aattctgcaa attaaaagcg acagctcact catctcatcg 2460  
 aagctatacc aaaagggat acacaaggat aacttggagc gttcgcagag acttacagag 2520  
 agtgtgaata cgattcccg taatgccacc gccaccgcgg tgagcagcag ctactcacc 2580  
 aaattcaata taaattcagc aaagccagcc gccgcgcgcg attcgcgtag cactggcaca 2640  
 gatccaagta caccacagaa cattctacag attaaagatt tgaatttccc ctcaaggctcg 2700  
 tcgtctcgca tatcccagcc ggagctgcac tacgccagcc tagatcttcc ccattgcagt 2760  
 ggccaaaatc cagctaaata cctgaagaga ggatcacgcg aatcgccgcc ggtgtccgca 2820  
 tgcccgagg atgggaatac ctatgcgaaa atcgactttg accaatccga ctctcttcc 2880  
 tcctcatcga acatatttaa tacgtaa 2907

<210> 2  
 <211> 2907  
 <212> DNA  
 <213> Drosophila melanogaster

<220>  
 <221> CDS  
 <222> (1)..(2907)

<400> 2  
 atg gca tca ata tcg gat gac ggc atg gcg ctg agt ggc tac ctc aag 48  
 Met Ala Ser Ile Ser Asp Asp Gly Met Ala Leu Ser Gly Tyr Leu Lys  
 1 5 10 15

aag ctg aag acc atg aag aag aag ttc ttt gtg ctg tac gag gag acg 96  
 Lys Leu Lys Thr Met Lys Lys Lys Phe Phe Val Leu Tyr Glu Glu Thr  
 20 25 30

agc act tcg gca gcc cgg ctg gag tac tac gat acc gaa aag aag ttc 144  
 Ser Thr Ser Ala Ala Arg Leu Glu Tyr Tyr Asp Thr Glu Lys Lys Phe  
 35 40 45

ctg caa aga gcc gag cca aaa agg gtt ata tat ctg aag aat tgc ttc 192  
 Leu Gln Arg Ala Glu Pro Lys Arg Val Ile Tyr Leu Lys Asn Cys Phe  
 50 55 60

aac atc aat cgc cgt ttg gac acc aag cat aga ttt gtc att gtg ctc 240  
 Asn Ile Asn Arg Arg Leu Asp Thr Lys His Arg Phe Val Ile Val Leu  
 65 70 75 80

tcc tcc aga gac ggt gga ttc ggc atc gtt ctc gag aac gaa aat gat 288  
 Ser Ser Arg Asp Gly Gly Phe Gly Ile Val Leu Glu Asn Glu Asn Asp  
 85 90 95

tta cgc aaa tgg ttg gac aaa cta cta gtt cta caa agg aac ata gcc 336  
 Leu Arg Lys Trp Leu Asp Lys Leu Leu Val Leu Gln Arg Asn Ile Ala  
 100 105 110

aat tcg aat gga aca gcg cac tca cct tat gac cac gtt tgg caa gtt 384  
 Asn Ser Asn Gly Thr Ala His Ser Pro Tyr Asp His Val Trp Gln Val  
 115 120 125

gtc att caa aag aag ggt att tcg gag aaa gtt gga atc acc gga acc 432  
 Val Ile Gln Lys Lys Gly Ile Ser Glu Lys Val Gly Ile Thr Gly Thr  
 130 135 140

tac cac tgt tgc ctt act tca aaa tcc ctg aca ttc gtg tgc att gga 480  
 Tyr His Cys Cys Leu Thr Ser Lys Ser Leu Thr Phe Val Cys Ile Gly  
 145 150 155 160

ccg gag aag acg ccc aat ggc gag gat cgc gtt gcg agc att gaa ata 528  
 Pro Glu Lys Thr Pro Asn Gly Glu Asp Arg Val Ala Ser Ile Glu Ile  
 165 170 175

ctt ttg acc acg atc agg cga tgc ggt cat gca tcc cca caa tgt ata 576  
 Leu Leu Thr Thr Ile Arg Arg Cys Gly His Ala Ser Pro Gln Cys Ile  
 180 185 190

ttc tac gtg gaa ctt ggc cgc caa agt gtc ttg gga tct ggt gat ctg 624  
 Phe Tyr Val Glu Leu Gly Arg Gln Ser Val Leu Gly Ser Gly Asp Leu  
 195 200 205



cgt ccc att cgc gcc tat tcg ata ggc aac aag gtt gag cat tta aag	1440
Arg Pro Ile Arg Ala Tyr Ser Ile Gly Asn Lys Val Glu His Leu Lys	
465 470 475 480	
ttt aat aag cgc ctg gga cac ttg aat gat acg gga cag aat ccg aat	1488
Phe Asn Lys Arg Leu Gly His Leu Asn Asp Thr Gly Gln Asn Pro Asn	
485 490 495	
cgc gtg cga gcc tac tcg gtt ggc tcc aaa tcg aag ata ccg cgc tgc	1536
Arg Val Arg Ala Tyr Ser Val Gly Ser Lys Ser Lys Ile Pro Arg Cys	
500 505 510	
gac ctg cag cga gtg gtc ctc gtg gag gac aat aaa cat gag ttc aca	1584
Asp Leu Gln Arg Val Val Leu Val Glu Asp Asn Lys His Glu Phe Thr	
515 520 525	
gcg aat agg agt cag agt agc att acc aag gaa gga acc agc tat ggc	1632
Ala Asn Arg Ser Gln Ser Ser Ile Thr Lys Glu Gly Thr Ser Tyr Gly	
530 535 540	
agc agt gcc aat cga caa aag aag tcc aca agt gct cca ctc ctc agt	1680
Ser Ser Ala Asn Arg Gln Lys Lys Ser Thr Ser Ala Pro Leu Leu Ser	
545 550 555 560	
ctg aag aac cag ata aac tcc gac cga atg agt gac tta atg gaa att	1728
Leu Lys Asn Gln Ile Asn Ser Asp Arg Met Ser Asp Leu Met Glu Ile	
565 570 575	
gat ttt tca caa gca acc aat ttg gaa aag cag aag ttc atc aag aat	1776
Asp Phe Ser Gln Ala Thr Asn Leu Glu Lys Gln Lys Phe Ile Lys Asn	
580 585 590	
aat gaa att ccg aaa tac att gaa aac gtg ttc cca aaa gcc ccg cga	1824
Asn Glu Ile Pro Lys Tyr Ile Glu Asn Val Phe Pro Lys Ala Pro Arg	
595 600 605	
acg gat agc tcc agc cta act ctg cac gcc aca agt caa aag gac att	1872
Thr Asp Ser Ser Ser Leu Thr Thr His Ala Thr Ser Gln Lys Asp Ile	
610 615 620	
ttc aat ggc acc aaa cta aat aac act gcg atc aca tcc gag gat ggt	1920
Phe Asn Gly Thr Lys Leu Asn Asn Thr Ala Ile Thr Ser Glu Asp Gly	
625 630 635 640	
tac ctc gag atg aag cca gtc ggt aat gga tac act ccc agt tcg aat	1968
Tyr Leu Glu Met Lys Pro Val Gly Asn Gly Tyr Thr Pro Ser Ser Asn	
645 650 655	
tgc ctg cca atg aaa gtg gag aaa ctc aag cta tcc gac tat cag aca	2016
Cys Leu Pro Met Lys Val Glu Lys Leu Lys Leu Ser Asp Tyr Gln Thr	
660 665 670	
gca ccg cca ctc acc gca aca gcc gca cca gtg cac gat tta aac aaa	2064
Ala Pro Pro Leu Thr Ala Thr Ala Ala Pro Val His Asp Leu Asn Lys	
675 680 685	
att agc aca tac aat ata tcc gct gag aaa tgg aga gaa cag ccc agc	2112
Ile Ser Thr Tyr Asn Ile Ser Ala Glu Lys Trp Arg Glu Gln Pro Ser	
690 695 700	
aga agc gag gaa aag aag tcg aac tcg cca ttg aat gac aac acc ttt	2160
Arg Ser Glu Glu Lys Lys Ser Asn Ser Pro Leu Asn Asp Asn Thr Phe	
705 710 715 720	

agc tcg aaa ccc aca aat gtc gag agt aca agc aaa agc cat gat gtt Ser Ser Lys Pro Thr Asn Val Glu Ser Thr Ser Lys Ser His Asp Val 725 730 735	2208
cat tca gca aat caa att gat tgc gag aaa gtg tgc gcg cag agc agc His Ser Ala Asn Gln Ile Asp Cys Glu Lys Val Cys Ala Gln Ser Ser 740 745 750	2256
gat aag cta aat aat cat ctg gcc gac aag att gtc gag aac aac aat Asp Lys Leu Asn Asn His Leu Ala Asp Lys Ile Val Glu Asn Asn Asn 755 760 765	2304
ttg gat ata ggc ggg cat gag gaa aag aag ttg gtt cat tcg ata agc Leu Asp Ile Gly Gly His Glu Glu Lys Lys Leu Val His Ser Ile Ser 770 775 780	2352
agc gaa gac tac aca caa atc aag gac aaa tcg aat gat ttc aca aaa Ser Glu Asp Tyr Thr Gln Ile Lys Asp Lys Ser Asn Asp Phe Thr Lys 785 790 795 800	2400
ttt aac gaa gcc ggc tac aaa att ctg caa att aaa agc gac agc tca Phe Asn Glu Ala Gly Tyr Lys Ile Leu Gln Ile Lys Ser Asp Ser Ser 805 810 815	2448
ctc atc tca tcg aag cta tac caa aag ggt ata cac aag gat aac ttg Leu Ile Ser Ser Lys Leu Tyr Gln Lys Gly Ile His Lys Asp Asn Leu 820 825 830	2496
gag cgt tcg cag aga ctt aca gag agt gtg aat acg att ccc gat aat Glu Arg Ser Gln Arg Leu Thr Glu Ser Val Asn Thr Ile Pro Asp Asn 835 840 845	2544
gcc acc gcc acc gcg gtg agc agc agc tca ctc acc aaa ttc aat ata Ala Thr Ala Thr Ala Val Ser Ser Ser Ser Leu Thr Lys Phe Asn Ile 850 855 860	2592
aat tca gca aag cca gcc gcc gcc gcc gat tcg cgt agc act ggc aca Asn Ser Ala Lys Pro Ala Ala Ala Asp Ser Arg Ser Thr Gly Thr 865 870 875 880	2640
gat cca agt aca cca cag aac att cta cag att aaa gat ttg aat ttc Asp Pro Ser Thr Pro Gln Asn Ile Leu Gln Ile Lys Asp Leu Asn Phe 885 890 895	2688
ccc tca agg tcg tcg tct cgc ata tcc cag ccg gag ctg cac tac gcc Pro Ser Arg Ser Ser Ser Arg Ile Ser Gln Pro Glu Leu His Tyr Ala 900 905 910	2736
agc cta gat ctt ccc cat tgc agt ggc caa aat cca gct aaa tac ctg Ser Leu Asp Leu Pro His Cys Ser Gly Gln Asn Pro Ala Lys Tyr Leu 915 920 925	2784
aag aga gga tca cgc gaa tcg ccg ccg gtg tcc gca tgc ccg gag gat Lys Arg Gly Ser Arg Glu Ser Pro Pro Val Ser Ala Cys Pro Glu Asp 930 935 940	2832
ggg aat acc tat gcg aaa atc gac ttt gac caa tcc gac tcc tct tcc Gly Asn Thr Tyr Ala Lys Ile Asp Phe Asp Gln Ser Asp Ser Ser Ser 945 950 955 960	2880
tcc tca tcg aac ata ttt aat acg taa Ser Ser Ser Asn Ile Phe Asn Thr 965	2907

<210> 3  
 <211> 968  
 <212> PRT  
 <213> Drosophila melanogaster

<400> 3  
 Met Ala Ser Ile Ser Asp Asp Gly Met Ala Leu Ser Gly Tyr Leu Lys  
 1 5 10 15  
 Lys Leu Lys Thr Met Lys Lys Lys Phe Phe Val Leu Tyr Glu Glu Thr  
 20 25 30  
 Ser Thr Ser Ala Ala Arg Leu Glu Tyr Tyr Asp Thr Glu Lys Lys Phe  
 35 40 45  
 Leu Gln Arg Ala Glu Pro Lys Arg Val Ile Tyr Leu Lys Asn Cys Phe  
 50 55 60  
 Asn Ile Asn Arg Arg Leu Asp Thr Lys His Arg Phe Val Ile Val Leu  
 65 70 75 80  
 Ser Ser Arg Asp Gly Gly Phe Gly Ile Val Leu Glu Asn Glu Asn Asp  
 85 90 95  
 Leu Arg Lys Trp Leu Asp Lys Leu Leu Val Leu Gln Arg Asn Ile Ala  
 100 105 110  
 Asn Ser Asn Gly Thr Ala His Ser Pro Tyr Asp His Val Trp Gln Val  
 115 120 125  
 Val Ile Gln Lys Lys Gly Ile Ser Glu Lys Val Gly Ile Thr Gly Thr  
 130 135 140  
 Tyr His Cys Cys Leu Thr Ser Lys Ser Leu Thr Phe Val Cys Ile Gly  
 145 150 155 160  
 Pro Glu Lys Thr Pro Asn Gly Glu Asp Arg Val Ala Ser Ile Glu Ile  
 165 170 175  
 Leu Leu Thr Thr Ile Arg Arg Cys Gly His Ala Ser Pro Gln Cys Ile  
 180 185 190  
 Phe Tyr Val Glu Leu Gly Arg Gln Ser Val Leu Gly Ser Gly Asp Leu  
 195 200 205  
 Trp Met Glu Thr Asp Asn Ala Ala Ile Ala Thr Asn Met His Asn Thr  
 210 215 220  
 Ile Leu Ser Ala Met Ser Ala Lys Thr Glu Ser Asn Thr Asn Leu Ile  
 225 230 235 240  
 Asn Val Tyr Gln Asn Arg Pro Asp Leu Ser His Glu Pro Met Arg Lys  
 245 250 255  
 Arg Ser Ser Ser Ala Asn Glu Ala Ser Lys Pro Ile Asn Val Asn Val  
 260 265 270  
 Ile Gln Asn Ser Gln Asn Ser Leu Glu Leu Arg Ser Cys Ser Ser Pro  
 275 280 285  
 His Asn Tyr Gly Phe Gly Arg Glu Arg Cys Asp Ser Leu Pro Thr Arg  
 290 295 300

Asn Gly Thr Leu Ser Glu Ser Ser Asn Gln Thr Tyr Phe Gly Ser Asn  
 305 310 315 320  
 His Gly Leu Arg Ser Asn Thr Ile Ser Gly Ile Arg Pro His Ser Thr  
 325 330 335  
 Asn Lys His Ser Asn Ser Pro Thr Phe Thr Met Pro Leu Arg Cys Ser  
 340 345 350  
 Glu Ser Glu Glu Ser Ser Ile Ser Val Asp Glu Ser Asp Asp Asn Gly  
 355 360 365  
 Ser Phe Ser His Tyr Arg Leu Asn Thr Arg Ser Ser Glu Thr Ala Ile  
 370 375 380  
 Pro Glu Glu Asn Ile Asp Asp Phe Ala Ser Ala Glu Leu Phe Ser Lys  
 385 390 395 400  
 Val Thr Glu Gln Asn Val Ser Asp Glu Asn Tyr Ile Pro Met Asn Pro  
 405 410 415  
 Val Asn Pro Thr Asp Ala Ile His Glu Lys Glu Lys Ala Asp Met Gln  
 420 425 430  
 Arg Leu Glu Asp Ala Ser Leu His Phe Asn Phe Pro Glu His Ala Ser  
 435 440 445  
 Glu Lys Leu Ala Lys Asp Phe Asp Leu Asp Ser Asp Asn Gln Cys Cys  
 450 455 460  
 Arg Pro Ile Arg Ala Tyr Ser Ile Gly Asn Lys Val Glu His Leu Lys  
 465 470 475 480  
 Phe Asn Lys Arg Leu Gly His Leu Asn Asp Thr Gly Gln Asn Pro Asn  
 485 490 495  
 Arg Val Arg Ala Tyr Ser Val Gly Ser Lys Ser Lys Ile Pro Arg Cys  
 500 505 510  
 Asp Leu Gln Arg Val Val Leu Val Glu Asp Asn Lys His Glu Phe Thr  
 515 520 525  
 Ala Asn Arg Ser Gln Ser Ser Ile Thr Lys Glu Gly Thr Ser Tyr Gly  
 530 535 540  
 Ser Ser Ala Asn Arg Gln Lys Lys Ser Thr Ser Ala Pro Leu Leu Ser  
 545 550 555 560  
 Leu Lys Asn Gln Ile Asn Ser Asp Arg Met Ser Asp Leu Met Glu Ile  
 565 570 575  
 Asp Phe Ser Gln Ala Thr Asn Leu Glu Lys Gln Lys Phe Ile Lys Asn  
 580 585 590  
 Asn Glu Ile Pro Lys Tyr Ile Glu Asn Val Phe Pro Lys Ala Pro Arg  
 595 600 605  
 Thr Asp Ser Ser Ser Leu Thr Leu His Ala Thr Ser Gln Lys Asp Ile  
 610 615 620  
 Phe Asn Gly Thr Lys Leu Asn Asn Thr Ala Ile Thr Ser Glu Asp Gly  
 625 630 635 640

Tyr	Leu	Glu	Met	Lys	Pro	Val	Gly	Asn	Gly	Tyr	Thr	Pro	Ser	Ser	Asn	
				645					650						655	
Cys	Leu	Pro	Met	Lys	Val	Glu	Lys	Leu	Lys	Leu	Ser	Asp	Tyr	Gln	Thr	
			660					665					670			
Ala	Pro	Pro	Leu	Thr	Ala	Thr	Ala	Ala	Pro	Val	His	Asp	Leu	Asn	Lys	
			675				680					685				
Ile	Ser	Thr	Tyr	Asn	Ile	Ser	Ala	Glu	Lys	Trp	Arg	Glu	Gln	Pro	Ser	
	690					695					700					
Arg	Ser	Glu	Glu	Lys	Lys	Ser	Asn	Ser	Pro	Leu	Asn	Asp	Asn	Thr	Phe	
705					710					715					720	
Ser	Ser	Lys	Pro	Thr	Asn	Val	Glu	Ser	Thr	Ser	Lys	Ser	His	Asp	Val	
				725					730					735		
His	Ser	Ala	Asn	Gln	Ile	Asp	Cys	Glu	Lys	Val	Cys	Ala	Gln	Ser	Ser	
			740					745					750			
Asp	Lys	Leu	Asn	Asn	His	Leu	Ala	Asp	Lys	Ile	Val	Glu	Asn	Asn	Asn	
	755						760					765				
Leu	Asp	Ile	Gly	Gly	His	Glu	Glu	Lys	Lys	Leu	Val	His	Ser	Ile	Ser	
	770					775					780					
Ser	Glu	Asp	Tyr	Thr	Gln	Ile	Lys	Asp	Lys	Ser	Asn	Asp	Phe	Thr	Lys	
785					790					795					800	
Phe	Asn	Glu	Ala	Gly	Tyr	Lys	Ile	Leu	Gln	Ile	Lys	Ser	Asp	Ser	Ser	
			805						810					815		
Leu	Ile	Ser	Ser	Lys	Leu	Tyr	Gln	Lys	Gly	Ile	His	Lys	Asp	Asn	Leu	
			820					825					830			
Glu	Arg	Ser	Gln	Arg	Leu	Thr	Glu	Ser	Val	Asn	Thr	Ile	Pro	Asp	Asn	
	835						840					845				
Ala	Thr	Ala	Thr	Ala	Val	Ser	Ser	Ser	Ser	Leu	Thr	Lys	Phe	Asn	Ile	
	850					855						860				
Asn	Ser	Ala	Lys	Pro	Ala	Ala	Ala	Ala	Asp	Ser	Arg	Ser	Thr	Gly	Thr	
865					870					875					880	
Asp	Pro	Ser	Thr	Pro	Gln	Asn	Ile	Leu	Gln	Ile	Lys	Asp	Leu	Asn	Phe	
				885					890					895		
Pro	Ser	Arg	Ser	Ser	Ser	Arg	Ile	Ser	Gln	Pro	Glu	Leu	His	Tyr	Ala	
			900					905					910			
Ser	Leu	Asp	Leu	Pro	His	Cys	Ser	Gly	Gln	Asn	Pro	Ala	Lys	Tyr	Leu	
	915						920					925				
Lys	Arg	Gly	Ser	Arg	Glu	Ser	Pro	Pro	Val	Ser	Ala	Cys	Pro	Glu	Asp	
	930					935					940					
Gly	Asn	Thr	Tyr	Ala	Lys	Ile	Asp	Phe	Asp	Gln	Ser	Asp	Ser	Ser	Ser	
945					950					955					960	
Ser	Ser	Ser	Asn	Ile	Phe	Asn	Thr									
			965													



<210> 4  
 <211> 5210  
 <212> DNA  
 <213> *Drosophila melanogaster*

<400> 4  
 agaacgactt tttcctcctt agtcagtcac aagaaaacta aagcttacca acaatacggc 60  
 gtgtattggt aaattattac aacaaataaa atattcaa atgtatttaa aatatagtaa 120  
 ccattaaaaa ataaaatcaa tatgcgaaac tttgtaattt cttactcatc cttgtttttt 180  
 gagcccgtt tcttaagtta aatcggttaa ataccagttt aatcatttca ttgtcctgat 240  
 ttcaggagct aattacattt taatctttgt ataaattcat aaaattaaaa tggaaatggt 300  
 taaccacata aaatatttgg gtatataaag tcgatacata ctttttaaaat tttgtttcat 360  
 acaagaatat ggaaagtaga taatttagtt accgattaaa acatttctaa aatacaaaaa 420  
 atttaaaatg atgattaaat aaaaaactgt tatactaaat ttaaacgaaa caaacgggtca 480  
 ttcgataact caattagtat cgaataagcc ggcggtgtaa tcgggttggc aactctcacc 540  
 ggtgtagaga tcgggatggc aacttcgtat tgttattcct atgctgcgat aacgataaca 600  
 gcaaagtgtc atcgcgaaata aatgtgggtt tgataataaa gaattgcgtt ggtgaacaat 660  
 aataatacaa atgctaaatg tatcgcgcg ataaactagta aacactgatt tcgcgcata 720  
 cgggcatacg ggcagctaga cgtcttaggt aacacatttc ccagccacat tggcggtgag 780  
 gtattatttc ccatatccat gtgcgtttgt aaatgatacc accagagtgt gccatatgta 840  
 tcgttggttg tacatacatg cctacgggga aaaataactc gcagatacat atgtatgtaa 900  
 gatgtattag aattccacag atatatgtac atataaatat atatatatat ttatgatgct 960  
 catctataaa acaaaatattg tacaaacata cgcgcgcacg tacttatgta tgtacatata 1020  
 catatataca tatatgtata ataaaatgag catctagctg cggttatctt aatgcaatgc 1080  
 gcagaaacct gaaaacgaaa taaacaatct ttacagcgcc agcacagtga gccaatattg 1140  
 aattcacaat tccacatcca attccgattc cgaattccat cgctttacat cctaattcga 1200  
 atacgtcgcg ccgcgtaagc tgcactcgaa tattgacata aacgacgtaa ttgcgtgttt 1260  
 tgattgcgat ttccgatgct cgatgttgac agacggcaag gatttttttt gccagccgac 1320  
 attgcgaatg cttttcgcgt gtttgcgttg tgaaaagcga tttgttggtc cggcagttgg 1380  
 aatgttttg tgctgtttat gcttagaaaa gcaaattgtat tgcacaaaac tcgtgtttcc 1440  
 tacattagta aagcctataa cttaggtata tgtttctaaa ttacaatgca aaaaataaaa 1500  
 aacattatac atgtgttcgt tctttaattt gaaaacagaa aagtgaaagc cttgcaaadc 1560  
 aaatatgtgt ccatatcgcc tactaataat ataaacacgt cgccttcag gaactaagat 1620  
 tggaaatcat ggcatacaata tcggatgacg gcatggcgct gagggtgtac ctcaagaagc 1680  
 tgaagaccat gaagaagaag ttctttgtgc tgtacgagga gacgagcact tcggcagccc 1740

ggctggagta ctacgatacc gaaaagaagt tcttgcaaag agccgagcca aaaaggggta 1800  
 tctatctgaa gaattgcttc aacatcaatc gccgttttga caccaagcat agatttgtca 1860  
 ttgtgctctc ctccagagac ggtggattcg gcatcgttct cgagaacgaa aatgatttac 1920  
 gcaaattggtt ggacaaacta ctagtcttac aaaggaacat agccaattcg aatggaacag 1980  
 cgcactcacc ttatggtatg ccaaataaac tataactacc agttagtatg aaacctaaac 2040  
 acttcatttc actttgcaga ccacgttttg caagttgtca ttcaaaagaa gggatatttcg 2100  
 gagaaagttg gaatcaccgg aacctaccac tgttgccctta cttcaaaatc cctgacattc 2160  
 gtgtgcattg gaccggagaa gacgccaat gccgaggatc gcgttgcgag cattgaaata 2220  
 cttttgacca cgatcaggcg gttagtgtt gccagcaaaa ctgcaaggga ttgtaaaata 2280  
 attcggactt aatttcagat gcggtcatgc atccccacaa tgtatattct acgtggaact 2340  
 tggcgcgcaa agtgtcttgg gatctgggtga tctgtggatg gagacggata acgcagctat 2400  
 tgctactaat atgcacaaca cgatactgag gtatttagct ctcattacaa ctaatccaag 2460  
 atttcatgat catcctacaa aacgacatag atagtttaag atatctccca gttaacttta 2520  
 ataattctgt gggttttttc tttcagcgct atgtcagcca aaacagagtc gaacacgaat 2580  
 ttaataaacg tttatcagaa cagacctgac ttaagtcacg agcccatgag aaagcgatcg 2640  
 tcgtctgcaa acgaagcatc gaagccgata aacgtaaattg tcatacaaaa tagtcaaaac 2700  
 tctctcgaat tgcgcagctg cagttcgccc cataactatg gtaaatactt caaatgtatg 2760  
 tttaaacgca aaattaatca aacgcaatcg tttcagggtt cggcagagag agatgcgata 2820  
 gcttaccaac cagaaatgga accctaagcg agtccagcaa tcaaacgtac tttggttcca 2880  
 accatggact gcgatccaat actatatctg gcatccgtcc gcactcaacc aacaagcata 2940  
 gtaatagtcc aacgttcacc atgccattaa gatgctcaga atccgaagag tcatcaatta 3000  
 gtgtcgatga atccgacgac aacggcagtt ttagccacta cagattaaag tgcgttgcta 3060  
 tcaaataata attatttaat aataatcacc atttcaattt ctagcacgcg gtcattctgag 3120  
 acggcaattc ctgaggaaaa cattgatgac tttgccagtg cggaattatt tagcaaaagtc 3180  
 accgaacaaa atggtaagcc aaacacaaaa acaatttttt aacatgaaaa gtagctaatac 3240  
 aattggcttt gtttaactgc agtaagtgc gaaaactaca taccgatgaa tccagtcaat 3300  
 cctaccgatg ctatccatga aaaggagaag gctgatatgc agagattgga agatgcttcg 3360  
 ctgcatttca actttccgga gcacgcgtcg gaaaagcttg ctaaggattt tgatctggac 3420  
 tctgataacc agtgagtaca catttcgctt caactgtgcc acgtaatgca atcaatcaca 3480  
 tcttggttaca gatgctgtcg tcccattcgc gcctattcga taggcaacaa ggttgagcat 3540  
 ttaaagttta ataagcgctt gggacacttg aatgatacgg gacagaatcc gaatcgcgtg 3600  
 cgagcctact cggttggctc caaatcgaag ataccgcgct gcgacctgca gcgagtggtc 3660

3720 3780 3840 3900 3960 4020 4080 4140 4200 4260 4320 4380 4440 4500 4560 4620 4680 4740 4800 4860 4920 4980 5040 5100 5160 5210

ctcgtggagg acaataaaca tgagttcaca gcgaatagga gtcagagtag cattaccaag 3720  
gaaggaacca gctatggcag cagtgccaat cgacaaaaga agtccacaag tgctccactc 3780  
ctcagtctga agaaccagat aaactccgac cgaatgagtg acttaatgga aattgatttt 3840  
tcacaagcaa ccaatttgga aaagcagaag ttcataaga ataataaat tccgaaatac 3900  
attgaaaacg tgttcccaaa agccccgcga acggatagct ccagcctaac tctgcacgcc 3960  
acaagtcaaa aggacatttt caatggcacc aaactaaata aactgcgat cacatccgag 4020  
gatggttacc tcgagatgaa gccagtcggt aatggataca ctcccagttc gaattgcctg 4080  
ccaatgaaag tggagaggct caagctatcc gactatcaga cagcaccgcc aatcacgcga 4140  
acagccgcac cagtgcacga tttaaacaaa attagcacat acaatatatc cgctgagaaa 4200  
tggagagaac agcccagcag aagcagaggaa aagaagtcga actcgccatt gaatgacaac 4260  
acctttggct tgaaaccac aaatgtcgag agtacaagca aaagccatga tgttcattca 4320  
gcaaatacaa ttgattccga gaaagtgtgc gcgcagagca gcgataagct aaataatctg 4380  
gccgacaaga ttgtcgagaa caacaatttg gatataggcg ggcatgagga aaagaagttg 4440  
gttcattcga taagcagcga agactacaca caaatcaagg acaaatcgaa tgatttcaca 4500  
aaatttaacg aagccggcta caaaattctg caaattaaaa gcgacagctc actcatctca 4560  
togaagctat accaaaaggg tatacacaag gataacttgg agcgttcgca gagacttacg 4620  
gagagtgtga atacgattcc cgataatgcc accgccaccg cggtagcag cagctcactc 4680  
accaaattca atataaattc agcaaagcca gccgccgccg ccgattcgcg tagcactggc 4740  
acagatccaa gtacaccaca gaacattcta cagattaaag atttgaattt cccctcaagg 4800  
tcgtcgtctc gcatatccca gccggagctg cactacgcca gcctagatct tccccattgc 4860  
agtggccaaa atccagctaa atacctgaag agaggatcac gcgaatcgcc gccggtgtcc 4920  
gcatgcccg aggatgggaa tacctatgcg aaaatcgact ttgaccaatc cgactcctct 4980  
tcctcctcat cgaacatatt taatacgtaa agttttgaaa tttatgaccc tatcctatat 5040  
atatgatttg tttaatatg tacatttatt gttaaatttc tctgacaagc aaagcttaca 5100  
attttggatg ctaataaata aattttattt aaattataat gatccctttg gacttttttt 5160  
ttttttggac taagaaatca ctactaaaga agggcttttc gagggttaaa 5210

1. [AMENDED] A method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable *chico* mutant insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size, cell size, development time or lipid level is determined whereby alterations of the body size, cell size, development time or lipid level are detectable in at least part of the animal.

4. [AMENDED] The method of claim 2 wherein the mutant does not comprise a wild-type *chico* gene.

5. [AMENDED] The method of claim 2 wherein the *Drosophila* mutant comprises one wild-type *chico* gene.

8. [AMENDED] The method of claim 2 wherein the *Drosophila* mutant comprises at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

10. [AMENDED] The method of claim 2 wherein the *Drosophila* lacks at least one *chico* gene.

12. [AMENDED] The method of claim 2 wherein the compound is a compound for the treatment of diabetes type 2.

13. [AMENDED] The method of claim 2 wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the whole animal.

14. [AMENDED] The method of claim 2 wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the head region only.

17. [AMENDED] The mutant of claim 15 that does not comprise a wild-type *chico* gene.

18. [AMENDED] The mutant of claim 15 that comprises one wild-type *chico* gene.

21. [AMENDED] The mutant of claim 15 comprising at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

23. [AMENDED] The mutant of claim 15 lacking at least one *chico* gene.

25. [AMENDED] The mutant of claim 15 which is a fly mutant.

26. [AMENDED] The mutant of claim 15 wherein at most one wild-type *chico* gene is found in the whole body of the insect.

27. [AMENDED] The mutant of claim 15 wherein at most one wild-type *chico* gene is found in the head region of the insect only.

28. [AMENDED] Use of an insect according to claim 15 as a means in screening compounds for modulating diseases.

29. [AMENDED] Use of an insect according to claim 15 as a means for searching for mutations involved directly or indirectly in the insulin signaling pathway.

30. [AMENDED] Use according to claim 22 characterized in that the disease is diabetes type 2.

31. [AMENDED] A method for generating a mutant insect, characterized in that adult animals are treated with a mutation generating means under mutation generating conditions, that thus treated insects are crossed to wild-type or mutant insects and that viable offsprings with altered cell number, cell size, developmental time or lipid levels are cultivated under suitable conditions.

Please add the following claims:

--32. The method of claim 31 wherein the adult animals are males.

33. The method of claim 31 wherein the treated insects are crossed with *chico* mutant insects.

34. The Mutant of claim 25 which is a *Drosophila* mutant.--

REMARKS


The foregoing amendments are made to change multiple dependencies. No new matter is introduced thereby and allowance of all claims 1-34 is hereby solicited.

Attached hereto as pages 6 through 9 is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned **"Version With Markings to Show Changes Made."**

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By

  
\_\_\_\_\_  
Jeffrey S. Sharp, Reg. No. 31,879  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

Chicago, Illinois  
December 20, 2001



VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 1, 4-5, 8-10, 12-14, 17-18, 21, 23, 25-31 have been amended as follows:

1. [AMENDED] A method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable *chico* mutant insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size<sub>a</sub> [and/or] cell size<sub>a</sub> [and/or] development time [and/] or lipid level is determined whereby alterations of the body size<sub>a</sub> [and/or] cell size<sub>a</sub> [and/or] development time [and/] or lipid level are detectable in at least part of the animal.

4. [AMENDED] The method of claim 2 [or 3] wherein the mutant does not comprise a wild-type *chico* gene.

5. [AMENDED] The method of claim 2 [or 3] wherein the *Drosophila* mutant comprises one wild-type *chico* gene.

8. [AMENDED] The method of claim 2 [anyone of claims 2 to 7] wherein the *Drosophila* mutant comprises at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

10. [AMENDED] The method of claim 2 [anyone of claims 2 to 9] wherein the *Drosophila* lacks at least one *chico* gene.

12. [AMENDED] The method of claim 2 [anyone of claims 1 to 11] wherein the compound is a compound for the treatment of diabetes type 2.

13. [AMENDED] The method of claim 2 [anyone of claims 1 to 12,] wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the whole animal.

14. [AMENDED] The method of claim 2 [anyone of claims 1 to 12,] wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the head region only.

17. [AMENDED] The mutant of claim 15 [or 16] that does not comprise a wild-type *chico* gene.

18. [AMENDED] The mutant of claim 15 [or 16] that comprises one wild-type *chico* gene.

21. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 20] comprising at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

23. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 22] lacking at least one *chico* gene.

25. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 24] which is a fly mutant[, in particular a *Drosophila* mutant].

26. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 25,] wherein at most one wild-type *chico* gene is found in the whole body of the insect.

27. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 25,] wherein at most one wild-type *chico* gene is found in the head region of the insect only.

28. [AMENDED] Use of an insect according to claim 15 [anyone of claims 15 to 27,] as a means in screening compounds for modulating diseases.

29. [AMENDED] Use of an insect according to claim 15 [anyone of claims 15 to 27] as a means for searching for mutations involved directly or indirectly in the insulin signaling pathway.

30. [AMENDED] Use according to claim 22 [or 23,] characterized in that the disease is diabetes type 2.

31. [AMENDED] A method for generating a mutant insect, characterized in that adult animals[, in particular males,] are treated with a mutation generating means under mutation generating conditions, that thus treated insects are crossed to wild-type or mutant insects[, in particular *chico* mutant insects,] and that viable offsprings with altered cell number, [and/or] cell size, [and/or] developmental time [and/]or lipid levels are cultivated under suitable conditions.

Claims 32-34 have been added as follows:

--32. The method of claim 31 wherein the adult animals are males.

33. The method of claim 31 wherein the treated insects are crossed with *chico* mutant insects.

34. The Mutant of claim 25 which is a *Drosophila* mutant.--

CLEAN VERSION OF CLAIMS AFTER AMENDMENT

1. A method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable *chico* mutant insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size, cell size, development time or lipid level is determined whereby alterations of the body size, cell size, development time or lipid level are detectable in at least part of the animal.

2. The method of claim 1 characterized in that the viable *chico* mutant insect comprises at most one wild-type *chico* gene.

3. The method of claim 2 wherein the mutant is a *Drosophila* mutant and wherein said mutant is treated in the egg or larvae stadium with said compound or compound generating means.

4. The method of claim 2 wherein the mutant does not comprise a wild-type *chico* gene.

5. The method of claim 2 wherein the *Drosophila* mutant comprises one wild-type *chico* gene.

6. The method of claim 5 wherein the wild-type *chico* gene encodes the amino acid sequence of Table 1 (SEQ. ID. NO. 2, 3).

7. The method of claim 6, wherein the wild-type *chico* gene is the genomic or the cDNA sequence represented in Table 1 (SEQ. ID. NO. 1, 2) or Table 2 (SEQ. ID. NO. 4).

8. The method of claim 2 wherein the *Drosophila* mutant comprises at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

9. The method of claim 7 wherein the *chico* mutation is the mutation described in Figure 3A.

10. The method of claim 2 wherein the *Drosophila* lacks at least one *chico* gene.

11. The method of claim 10 wherein the mutant lacks both *chico* genes.

12. The method of claim 2 wherein the compound is a compound for the treatment of diabetes type 2.

13. The method of claim 2 wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the whole animal.

14. The method of claim 2 wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the head region only.

15. A viable insect mutant comprising at most one wild-type *chico* gene in at least a part of its body and said at least one part of the body shows reduced size.

16. The mutant of claim 15 that does not comprise as sole *chico* genes two *chico* genes.

17. The mutant of claim 15 that does not comprise a wild-type *chico* gene.

18. The mutant of claim 15 that comprises one wild-type *chico* gene.

19. The mutant of claim 18 wherein the wild-type *chico* gene encodes the amino acid sequence of Table 1 (SEQ. ID. NO. 2, 3).

20. The mutant of claim 19, wherein the wild-type *chico* gene is the genomic or the cDNA sequence represented in Table 2 (SEQ. ID NO. 4) or Table 1 (SEQ. ID. NO. 1, 2).

21. The mutant of claim 15 comprising at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

22. The mutant of claim 21 wherein the *chico* mutation is the mutation described in Figure 3A.

23. The mutant of claim 15 lacking at least one *chico* gene.

24. The mutant of claim 15 lacking both *chico* genes.

25. The mutant of claim 15 which is a fly mutant.

26. The mutant of claim 15 wherein at most one wild-type *chico* gene is found in the whole body of the insect.

27. The mutant of claim 15 wherein at most one wild-type *chico* gene is found in the head region of the insect only.

28. Use of an insect according to claim 15 as a means in screening compounds for modulating diseases.

29. Use of an insect according to claim 15 as a means for searching for mutations involved directly or indirectly in the insulin signaling pathway.

30. Use according to claim 22 characterized in that the disease is diabetes type 2.



31. A method for generating a mutant insect, characterized in that adult animals are treated with a mutation generating means under mutation generating conditions, that thus treated insects are crossed to wild-type or mutant insects[, in particular *chico* mutant insects,] and that viable offsprings with altered cell number, cell size, developmental time [and/]or lipid levels are cultivated under suitable conditions.

32. The method of claim 31 wherein the adult animals are males.

33. The method of claim 31 wherein the treated insects are crossed with *chico* mutant insects.

34. The Mutant of claim 25 which is a *Drosophila* mutant.

## IN VIVO INSECT MODEL SYSTEM FOR TYPE-2 DIABETES

Technical Field

The present invention concerns a tool for the  
5 investigation of diseases, in particular type-2 diabetes.  
The invention especially concerns an in vivo model that  
enables e.g. the screening of compounds suitable for  
therapy and diagnosis.

Background Art

10

Due to its homology with man, *Drosophila*  
might be a very useful in vivo model for the  
investigation of human diseases and for the drug  
15 screening, as long as the target to be investigated leads  
to an easily detectable change in the fly, such as size  
reduction.

Factors influencing the growth have already  
been extensively studied.

20

Much of the knowledge about growth regulation  
stems from studies done using tissue culture cell lines.  
A large number of peptide growth factors have been  
identified that stimulate cell division and survival of  
cultured cells. These observations have led to the  
25 hypothesis that regulation of overall growth is  
controlled primarily by coordinating cell cycle  
progression and cell survival (Raff, 1996). Although  
during development, the regulation of the cell cycle is  
tightly coupled to morphogenetic events (Edgar et al,  
30 1994), several lines of evidence suggest that it may not  
be the primary determinant of growth regulation. Overall  
growth of an organ appears to be monitored by measuring  
total organ tissue volume and not by counting cell  
divisions. In mosaic wings consisting of haploid and  
35 diploid cells, haploid cells produce a normal sized  
compartment consisting of twice the number of cells  
(Santamaria, 1983). Moreover, if mitosis is blocked by

use of a temperature sensitive mutation in *cdc2* (Weigmann et al., 1997) or by overexpression of RBF, which is a negative regulator of the cell cycle (Neufeld et al., 1998), the result is normal sized compartments consisting of fewer but larger cells. Conversely, accelerating the cell cycle by overexpression of E2F, a positive cell cycle regulator produces more and smaller cells but does not alter clone size (Neufeld et al. 1998). Thus, changing the length of the cell cycle does not directly affect overall organ growth, which indicates that cellular growth can occur independently of cell cycle control.

In higher vertebrates, hormones and growth factors play an important role in the control of overall growth because they orchestrate cell growth, cell cycle, and cell survival. Reducing or increasing levels of growth hormone or of its mediators, IGF-1 and its receptor (IGFR), dramatically influence body and organ size (for review see Stewart and Rotwein, 1996). The control of cell survival can be an essential factor influencing overall growth (Raff, 1996).

Overall growth (and in some cases cell size) is also affected by the availability of nutrients. Many organisms have developed special survival strategies for periods of growth during low nutrition. Under inadequate nutritional conditions yeast cells, for example, reduce growth and divide at a smaller size (Thomas and Hall, 1997), whereas nematodes like *C. elegans* enter a diapause called the dauer stage (reviewed in Riddle, 1988; Cassada and Russel, 1975). When in this state, larvae arrest development in a sexually immature stage, alter their metabolism to increase the storage of fat, and live up to three times as long as under non-starved conditions (Cassada and Russel, 1975). Dauer formation in *C. elegans* is dependent on the cooperation of the insulin and TGF- $\beta$  signalling pathways (Kimura et al., 1997). Raising *Drosophila* under adverse food conditions also results in

the production of small flies with fewer and smaller cells (Robertson, 1959; Bryant and Simpson, 1984). Still, little is known in higher organisms about how growth is controlled at the cellular level. In *Drosophila*, a class of mutations known as *Minutes* (*M*) dominantly delay development, and in some cases result in reduced body size. Some of the *M* genes encode ribosomal proteins and are thought to slow down growth by reducing protein synthesis (Lindsley and Zimm, 1992). Partial loss of function mutations in the *Drosophila myc* gene, diminutive, cause a reduction in overall body size (Gallant et al., 1996).

There has also already been described a P element induced *Drosophila* mutation, *fs(2)4<sup>1</sup>*, as a female sterile, male fertile, mutation (Berg and Spradling, 1991). However, there is nothing disclosed about size differences or the place of the P-element induced mutation.

Thus, none of the documents of the state of the art suggests any applicability of such flies in the investigation of human diseases and/or for drug screening.

It is therefore still very much desired to get an in vivo model for such investigations.

#### Disclosure of the Invention

It has now surprisingly been found that the mutant strain, the phenotype of which was described by Berg and Spradling in 1991, after 7 years of storage lost its viability. The originally described female sterile phenotype could be restored by recombination. After recombination, two further phenotypes associated with the defect *fs(2)4<sup>1</sup>* could be observed: Homozygous animals are reduced in size and adult flies have increased lipid levels. Furthermore it was discovered that the mutation

is located in the gene coding for the homolog of the insulin receptor substrate (IRS 1-4).

Due to the observed reduction in the body size, the gene affected by the P element and the mutant animal, in particular the mutant *Drosophila*, with a size reducing defect in said gene, are named *chico* which means small boy in Spanish.

The observed alterations in the body size and other characteristics of the mutant make such mutant animals very useful tools in the investigation of interactions with and mutations of the insulin signaling pathway.

Thus, one object of the present invention was to provide a method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, wherein a viable insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size and/or cell size and/or development time and/or lipid level is determined whereby alterations of the body size and/or cell size and/or development time and/or lipid level are detectable in at least part of the animal. Preferred animals for use in such method are animals with reduced *chico* function, e.g. with at least one nucleotide sequence being a *chico* mutation.

Another object of the present invention was to provide the *chico* gene and *chico* mutations, in particular size reducing *chico* mutations. *Chico* is of particular interest, since also homozygosity for *chico* causes only semi-lethality. Additionally, an overall delay in development has been observed. Homozygous *chico* animals eclose two or three days after their heterozygous siblings. Under noncrowded culture conditions, homozygous *chico* mutant females can produce few viable progeny lacking both maternal and zygotic *chico* function.

In the scope of the present invention, animal means insects, whereby preferred insects are flies and a preferred fly is *Drosophila*. Where in the scope of the further general description fly or *Drosophila* is mentioned, it has to be understood that - in not preferred embodiments of the present invention - also other animals of the above definition are encompassed in the respective disclosure.

The fact that insects with a mutation within the insulin signaling pathway show altered characteristics is e.g. shown in that mutant flies homozygous for *chico* are markedly reduced in size but survive. This shows that a total loss of *chico* activity is not lethal. Obviously, the insulin receptor (INR) pathway is thus that *chico* can - at least partially - be bypassed.

Due to this finding, *chico* mutant animals are not only suitable for drug screening, but also enable the search for possible further defects in the INR pathway or therewith interacting factors.

While for drug screening flies with two inactive *chico* mutants, one inactive *chico* mutant and one *chico* gene lost, or both *chico* genes lost are preferred, also flies with a reduced *chico* activity can be used as long as the mutant flies are sufficiently distinguishable from wild-type flies.

Such flies with reduced *chico* activity can either have two *chico* mutations with reduced activity both, one *chico* mutation with no and one *chico* mutation with reduced activity, or one *chico* totally lacking and one *chico* mutation with reduced activity.

Besides of drug screening, such *chico* mutant flies can also be used as sensitized model systems to find other key components in the INR pathway.

Although heterozygous *chico* flies with one functional *chico* are not easily distinguishable from wild-type flies, they are interesting models for finding

further key components in the INR pathway, whereby flies sensitized in *chico* and having a further non-lethal defect in another compound involved in the INR pathway, are again useful model systems for drug screening and  
5 search for further key components.

Flies comprising, besides *chico*, further mutations can be obtained by several methods known to the skilled person such as mutations induced by P element, chemical compounds, radiation etc. If a mutation of a  
10 known key component shall be introduced, this can furthermore be performed by destroying at least one respective wild-type gene and insertion of the desired mutation.

The preferred animal - as already mentioned  
15 above - is *Drosophila* due to the great knowledge on this fly, the high conservation of the genome and the fast reproduction. However, the high conservation makes also other insects suitable model systems, in particular other flies.

20 The applicability of *chico* mutations is not only particularly broad due to their specific characteristics, but also due to the fact that it is the first coupling element within the cell and thus situated at the very beginning of the cascade of components  
25 involved in the INR pathway.

The method of screening for compounds influencing the INR pathway involves *chico* mutant animals such that e.g. a single drug or a combination of two or more drugs is applied to the animal in as early  
30 development stage, e.g. to the larvae of said *chico* mutant flies and that at least one difference between treated and non treated animals in the juvenile or adult state, e.g. larvae or flies, respectively, is determined.

The time of the application is not critical.  
35 The application can be performed by injection, whereby a preferred method is injection into the egg, and a much preferred method is injection into the larvae. However,

for some applications, injection into the adult animal is also possible.

The determination of differences between treated and non-treated animals can be performed by measuring the weight, the cell size, the cell number or the lipid content per weight. The fact that *chico* affects not either cell size or cell number, but both is a very favorable characteristic if e.g. a second defect were present affecting either the number or the size only.

Thus, *chico* mutant flies, whether they have only *chico* mutations or furthermore another mutation in the INR pathway, are very useful tools for the screening of compounds improving the INR signalling pathway.

#### Brief Description of the Drawings

The invention will be better understood and objects other than those set forth above will become apparent when consideration is given to the following detailed description thereof. Such description makes reference to the annexed drawings, wherein:

Figure 1A shows the body size reduction of homozygous mutant animals at different development stages, whereby *Drosophila* with one wild-type *chico* (+) and one inactive *chico* allele (-) are marked as (+/-), *Drosophila* with two inactive *chico* alleles as (-/-) and control flies with two wild-type *chico* as (+/+), and whereby the *chico*<sup>-/-</sup> egg was derived from heterozygous *chico* females in which *chico*<sup>-/-</sup> germline clones had been generated. The *chico*<sup>1</sup> allele (P element insertion allele) was used for germ-line clones. In comparison, a heterozygous *chico* mutant egg (*chico*<sup>+/-</sup>) is shown. Homozygous *chico*<sup>-/-</sup> larvae, pupae and adults were derived from heterozygous flies carrying the *chico*<sup>2</sup> allele.

Figure 1B shows the body weight of individual flies (n = 20) whereby the weights of y w control flies



(+/+), heterozygous (+/-) and homozygous mutant (-/-) *chico* flies are shown.

Figure 2 represents comparison of the cell size distribution of heterozygous (+/-) and homozygous mutant (-/-) *chico* wing disc cells determined by FACS analysis, whereby

Figure 2A represents dot blots of heterozygous (+/-) *chico* wing disc cells displaying forward scatter (FSC), which is a measurement for cell size, and side scatter (SSC), which is a measurement for cell granulation, and whereby

Figure 2B is an analogue representation as Figure 2A for homozygous (-/-) *chico* wing disc cells.

Figure 2C is a histogram that displays cell size (FSC) and cell number. Comparison of the mean value of the FSC in Figure 1A and Figure 1B of the gated cell population (R1) reveals that the mean value of the FSC of homozygous mutant *chico* cells is reduced by 10-14 percent in three independent experiments compared with the mean value of the FSC of heterozygous cells.

Figure 3A shows the genomic structure of the *chico* locus at 31B-C with the putative transcriptional start site lying 221 bp 3' from the end of *bsk* encoding DJNK. *ME31B* encodes a DEAD box RNA helicase (de Valoir et al., 1991). Comparison of the genomic and cDNA sequence revealed that the *chico* transcript contains 9 exons with the putative translational start site in the second exon. Black boxes represent translated exons and open boxes indicate untranslated exons. See text for details concerning the P element insertion, the deficiency chromosome, and the rescue constructs. H = HindIII; E = EcoRI.

Figure 3B shows the translated amino acid sequence wherein the black-boxed sequence represents the PH domain and the grey-boxed sequence the PTB domain, respectively, and wherein the putative DRK binding site

(YQN) and the two putative p60 PI3K binding sites (YIPM and YLEM) are highlighted.

Figure 3C shows a PH and PTB domain alignment, wherein the PH domain and the PTB domain of CHICO were aligned to human IRS-1,2,4 and mouse IRS-3, and wherein the dark boxes indicate amino acid identity, while the grey boxes indicate amino acid similarity. The lowercase letters in the consensus line represent identity in 3-4 of the proteins, while upper case letters represent identity in all proteins. The percentage identity was calculated by comparing CHICO individually to each mammalian IRS, and then averaging the four separate identities.

Figure 4A is a tangential section through an eye containing a CHICO (-/-) clone, whereby the *chico* (-/-) clone is recognized by the lack of pigment (bright ? passages). Within the clone, all photoreceptor (PR) cells are reduced in size by about 50 percent compared with wild-type PR cells (dark). At the border of the clone ommatidia composed of wild-type and small *chico*<sup>-/-</sup> mutant PR cells (arrow head) are visible, indicating that CHICO controls cell size autonomously. The numbers represent PR cells R1-R7.

Figure 4B is a comparison of wild-type flies with flies in which the *chico* function in the eye imaginal disc cells has been removed, thereby generating flies with a strongly reduced head capsule and reduced eyes, whereas the proboscis and the rest of the body are of wild-type size. The flies compared were of the following genotypes: (B, left panel) *y w ey-Flp; chico*<sup>1</sup> *FRT40 / P(w<sup>+</sup>) 1(2)2L-3.1 FRT40; P(w<sup>+</sup> chico genomic rescue construct pCSR4)/+*, (B, right panel) *y w ey-Flp; chico*<sup>1</sup> *FRT40 / P(w<sup>+</sup>) 1(2)2L-3.1 FRT40*, (C, scanning electron micrograph, left panel) *y w ey-Flp; chico*<sup>1</sup> *FRT40 / CyO*, (C, scanning electron micrograph, right panel) *y w ey-Flp; chico*<sup>1</sup> *FRT40 / P(w<sup>+</sup>) 1(2)2L-3.1 FRT40*.

Figure 4C is an enlarged view of the head region of Figure 4B.

Figure 5A shows the fresh and dry weight of individual wild-type (+/+), heterozygous (+/-), and homozygous (-/-) *chico* mutant males, whereby measurement was made of individual adult males (n = 10) reared under the same growth conditions and analyzed three days after eclosion. The dry weight of wild-type, heterozygous and homozygous mutant males is approximately 28 percent of the corresponding fresh weight.

Figure 5B shows lipid, protein and glycogen contents of the same analytical group as in Figure 1A. As can be seen homozygous *chico* mutant (-/-) males contain almost twice as much lipid calories per milligram fresh weight compared with heterozygous (+/-) or wild-type (+/+) flies.

#### Modes for carrying out the invention

In order to use insects, in particular *Drosophila* mutants as in vivo monitoring system, the function of the defect gene and differences between wild-type *Drosophila* and *chico* mutant *Drosophila* have been studied.

Thereby it was found that *chico* encodes a homologue of vertebrate insulin receptor substrates, IRS1-4.

The insertion site of the P element in *chico*<sup>1</sup> was mapped 1.5 kb downstream of the *bsk* gene (Figure 3A). Isolation and analysis of partial cDNA clones, a full length EST clone and the corresponding genomic sequence flanking the P element insertion, indicated that the *chico* gene consists of a single transcription unit of 3.6 kb with 9 exons. The P element insertion is located 80 bp downstream of the putative translation initiation site in the PH domain (see below). The open reading frame codes for a protein product of 967 amino acids with a

calculated molecular weight of 97 kd. The CHICO amino acid sequence exhibits the strongest similarity with members of a family of vertebrate insulin receptor substrate proteins known as IRS1-4. Vertebrate IRS family members are characterized by an N-terminal pleckstrin homology (PH) domain, a phosphotyrosine binding (PTB) domain and by a number of phosphotyrosine motifs that can serve as docking sites for SH2-containing proteins (for review see Yenush and White, 1997).

10           The cDNA sequence (SEQ ID NOs 1, 2) of wild-type *chico* is shown in Table 1 together with the respective protein sequence, (SEQ ID NOs 2, 3) and the genomic DNA sequence (SEQ ID NO 4) is found in Table 2 below.

15           While the cDNA sequence shows the coding sequence only, the genomic sequence comprises functional flanking parts.

20           Furthermore, it has to be understood that all sequence related statements - also without specific mention - also concerns the complementary strand.

Table 1: cDNA and Protein Sequence

	154/1	184/11
5	214/21	244/31
	ATG GCA TCA ATA TCG GAT GAC GGC ATG GCG CTG AGT GGC TAC CTC AAG AAG CTG AAG ACC ATG AAG AAG AAG TTC TTT GTG CTG TAC GAG GAG ACG AGC ACT TCG GCA GCC CGG CTG GAG Met ala ser ile ser asp asp gly met ala leu ser gly tyr leu lys lys leu lys thr met lys lys lys phe phe val leu tyr glu glu thr ser thr ser ala ala arg leu glu 274/41 334/61	
		304/51 364/71
20	TAC TAC GAT ACC GAA AAG AAG TTC CTG CAA AGA GCC GAG CCA AAA AGG GTT ATA TAT CTG AAG AAT TGC TTC AAC ATC AAT CGC CGT TTG GAC ACC AAG CAT AGA TTT GTC ATT GTG CTC tyr tyr asp thr glu lys lys phe leu gln arg ala glu pro lys arg val ile tyr leu lys asn cys phe asn ile asn arg arg leu asp thr lys his arg phe val ile val leu 394/81 454/101	
30		424/91 484/111
	TCC TCC AGA GAC GGT GGA TTC GGC ATC GTT CTC GAG AAC GAA AAT GAT TTA CGC AAA TGG TTG GAC AAA CTA CTA GTT CTA CAA AGG AAC ATA GCC AAT TCG AAT GGA ACA GCG CAC TCA ser ser arg asp gly gly phe gly ile val leu glu asn glu asn asp leu arg lys trp leu asp lys leu leu val leu gln arg asn ile ala asn ser asn gly thr ala his ser 514/121 574/141	
45		544/131 604/151
	CCT TAT GAC CAC GTT TGG CAA GTT GTC ATT CAA AAG AAG GGT ATT TCG GAG AAA GTT GGA ATC ACC GGA ACC TAC CAC TGT TGC CTT ACT TCA AAA TCC CTG ACA TTC GTG TGC ATT GGA pro tyr asp his val trp gln val val ile gln lys lys gly ile ser glu lys val gly ile thr gly thr tyr his cys cys leu thr ser lys ser leu thr phe val cys ile gly 634/161 694/181	
55		664/171 724/191

CCG GAG AAG ACG CCC AAT GGC GAG GAT CGC GTT GCG AGC ATT GAA ATA CTT  
 TTG ACC  
 ACG ATC AGG CGA TGC GGT CAT GCA TCC CCA CAA TGT ATA TTC TAC GTG GAA  
 CTT GGC  
 5 CGC CAA  
 pro glu lys thr pro asn gly glu asp arg val ala ser ile glu ile leu  
 leu thr  
 thr ile arg arg cys gly his ala ser pro gln cys ile phe tyr val glu  
 leu gly  
 10 arg gln  
 754/201 784/211  
 814/221 844/231

AGT GTC TTG GGA TCT GGT GAT CTG TGG ATG GAG ACG GAT AAC GCA GCT ATT  
 15 GCT ACT  
 AAT ATG CAC AAC ACG ATA CTG AGC GCT ATG TCA GCC AAA ACA GAG TCG AAC  
 ACG AAT  
 TTA ATA  
 ser val leu gly ser gly asp leu trp met glu thr asp asn ala ala ile  
 20 ala thr  
 asn met his asn thr ile leu ser ala met ser ala lys thr glu ser asn  
 thr asn  
 leu ile  
 874/241 904/251  
 25 934/261 964/271

AAC GTT TAT CAG AAT AGA CCT GAC TTA AGT CAC GAG CCC ATG AGA AAG CGA  
 TCG TCG  
 TCT GCA AAC GAA GCA TCG AAG CCG ATA AAC GTA AAT GTC ATA CAA AAT AGT  
 30 CAA AAC  
 TCT CTC  
 asn val tyr gln asn arg pro asp leu ser his glu pro met arg lys arg  
 ser ser  
 ser ala asn glu ala ser lys pro ile asn val asn val ile gln asn ser  
 35 gln asn  
 ser leu  
 994/281 1024/291  
 1054/301 1084/311

GAA TTG CGC AGC TGC AGT TCG CCC CAT AAC TAT GGT TTC GGC AGA GAG AGA  
 40 TGC GAT  
 AGC TTA CCA ACC AGA AAT GGA ACC CTA AGC GAG TCC AGC AAT CAA ACG TAC  
 TTT GGT  
 TCC AAC  
 45 glu leu arg ser cys ser ser pro his asn tyr gly phe gly arg glu arg  
 cys asp  
 ser leu pro thr arg asn gly thr leu ser glu ser ser asn gln thr tyr  
 phe gly  
 ser asn  
 50 1114/321 1144/331  
 1174/341 1204/351

CAT GGA CTG CGA TCC AAT ACT ATA TCT GGC ATC CGT CCG CAC TCA ACC AAC  
 AAG CAT  
 55 AGT AAT AGT CCA ACG TTC ACC ATG CCA TTA AGA TGC TCA GAA TCC GAA GAG  
 TCA TCA  
 ATT AGT  
 his gly leu arg ser asn thr ile ser gly ile arg pro his ser thr asn  
 lys his

ser asn ser pro thr phe thr met pro leu arg cys ser glu ser glu glu  
 ser ser  
 ile ser  
 1234/361 1264/371  
 5 1294/381 1324/391

GTC GAT GAA TCC GAC GAC AAC GGC AGT TTT AGC CAC TAC AGA TTA AAC ACG  
 CGG TCA  
 TCT GAG ACG GCA ATT CCT GAG GAA AAC ATT GAT GAC TTT GCC AGT GCG GAA  
 10 TTA TTT  
 AGC AAA  
 val asp glu ser asp asp asn gly ser phe ser his tyr arg leu asn thr  
 arg ser  
 ser glu thr ala ile pro glu glu asn ile asp asp phe ala ser ala glu  
 15 leu phe  
 ser lys  
 1354/401 1384/411  
 1414/421 1444/431

20 GTC ACC GAA CAA AAT GTA AGT GAC GAA AAC TAC ATA CCG ATG AAT CCA GTC  
 AAT CCT  
 ACC GAT GCT ATC CAT GAA AAG GAG AAG GCT GAT ATG CAG AGA TTG GAA GAT  
 GCT TCG  
 CTG CAT  
 25 val thr glu gln asn val ser asp glu asn tyr ile pro met asn pro val  
 asn pro  
 thr asp ala ile his glu lys glu lys ala asp met gln arg leu glu asp  
 ala ser  
 leu his  
 30 1474/441 1504/451  
 1534/461 1564/471

TTC AAC TTT CCG GAG CAC GCG TCG GAA AAG CTT GCT AAG GAT TTT GAT CTG  
 GAC TCT  
 35 GAT AAC CAA TGC TGT CGT CCC ATT CGC GCC TAT TCG ATA GGC AAC AAG GTT  
 GAG CAT  
 TTA AAG  
 phe asn phe pro glu his ala ser glu lys leu ala lys asp phe asp leu  
 asp ser  
 40 asp asn gln cys cys arg pro ile arg ala tyr ser ile gly asn lys val  
 glu his  
 leu lys  
 1594/481 1624/491  
 1654/501 1684/511

45 TTT AAT AAG CGC CTG GGA CAC TTG AAT GAT ACG GGA CAG AAT CCG AAT CGC  
 GTG CGA  
 GCC TAC TCG GTT GGC TCC AAA TCG AAG ATA CCG CGC TGC GAC CTG CAG CGA  
 GTG GTC  
 50 CTC GTG  
 phe asn lys arg leu gly his leu asn asp thr gly gln asn pro asn arg  
 val arg  
 ala tyr ser val gly ser lys ser lys ile pro arg cys asp leu gln arg  
 val val  
 55 leu val  
 1714/521 1744/531  
 1774/541 1804/551

60 GAG GAC AAT AAA CAT GAG TTC ACA GCG AAT AGG AGT CAG AGT AGC ATT ACC  
 AAG GAA

GGG ACC AGC TAT GGC AGC AGT GCC AAT CGA CAA AAG AAG TCC ACA AGT GCT  
CCA CTC  
CTC AGT  
5 glu asp asn lys his glu phe thr ala asn arg ser gln ser ser ile thr  
lys glu  
gly thr ser tyr gly ser ser ala asn arg gln lys lys ser thr ser ala  
pro leu  
leu ser  
1834/561 1864/571  
10 1894/581 1924/591  
  
CTG AAG AAC CAG ATA AAC TCC GAC CGA ATG AGT GAC TTA ATG GAA ATT GAT  
TTT TCA  
CAA GCA ACC AAT TTG GAA AAG CAG AAG TTC ATC AAG AAT AAT GAA ATT CCG  
15 AAA TAC  
ATT GAA  
leu lys asn gln ile asn ser asp arg met ser asp leu met glu ile asp  
phe ser  
gln ala thr asn leu glu lys gln lys phe ile lys asn asn glu ile pro  
20 lys tyr  
ile glu  
1954/601 1984/611  
2014/621 2044/631  
  
25 AAC GTG TTC CCA AAA GCC CCG CGA ACG GAT AGC TCC AGC CTA ACT CTG CAC  
GCC ACA  
AGT CAA AAG GAC ATT TTC AAT GGC ACC AAA CTA AAT AAC ACT GCG ATC ACA  
TCC GAG  
GAT GGT  
30 asn val phe pro lys ala pro arg thr asp ser ser ser leu thr leu his  
ala thr  
ser gln lys asp ile phe asn gly thr lys leu asn asn thr ala ile thr  
ser glu  
asp gly  
35 2074/641 2104/651  
2134/661 2164/671  
  
TAC CTC GAG ATG AAG CCA GTC GGT AAT GGA TAC ACT CCC AGT TCG AAT TGC  
CTG CCA  
40 ATG AAA GTG GAG AAA CTC AAG CTA TCC GAC TAT CAG ACA GCA CCG CCA CTC  
ACC GCA  
ACA GCC  
tyr leu glu met lys pro val gly asn gly tyr thr pro ser ser asn cys  
leu pro  
45 thr lys val glu lys leu lys leu ser asp tyr gln thr ala pro pro leu  
thr ala  
2194/681 2224/691  
2254/701 2284/711  
  
50 GCA CCA GTG CAC GAT TTA AAC AAA ATT AGC ACA TAC AAT ATA TCC GCT GAG  
AAA TGG  
AGA GAA CAG CCC AGC AGA AGC GAG GAA AAG AAG TCG AAC TCG CCA TTG AAT  
GAC AAC  
55 ACC TTT  
ala pro val his asp leu asn lys ile ser thr tyr asn ile ser ala glu  
lys trp  
arg glu gln pro ser arg ser glu glu lys lys ser asn ser pro leu asn  
60 asp asn  
thr phe



2314/721  
 2374/741

2344/731  
 2404/751

5 AGC TCG AAA CCC ACA AAT GTC GAG AGT ACA AGC AAA AGC CAT GAT GTT CAT  
 TCA GCA  
 AAT CAA ATT GAT TGC GAG AAA GTG TGC GCG CAG AGC AGC GAT AAG CTA AAT  
 AAT CAT  
 CTG GCC  
 ser ser lys pro thr asn val glu ser thr ser lys ser his asp val his  
 10 ser ala  
 asn gln ile asp cys glu lys val cys ala gln ser ser asp lys leu asn  
 asn his  
 leu ala  
 2434/761  
 15 2494/781

2464/771  
 2524/791

20 GAC AAG ATT GTC GAG AAC AAC AAT TTG GAT ATA GGC GGG CAT GAG GAA AAG  
 AAG TTG  
 GTT CAT TCG ATA AGC AGC GAA GAC TAC ACA CAA ATC AAG GAC AAA TCG AAT  
 GAT TTC  
 ACA AAA  
 asp lys ile val glu asn asn asn leu asp ile gly gly his glu glu lys  
 lys leu  
 val his ser ile ser ser glu asp tyr thr gln ile lys asp lys ser asn  
 25 asp phe  
 thr lys  
 2554/801  
 2614/821

2584/811  
 2644/831

30 TTT AAC GAA GCC GGC TAC AAA ATT CTG CAA ATT AAA AGC GAC AGC TCA CTC  
 ATC TCA  
 TCG AAG CTA TAC CAA AAG GGT ATA CAC AAG GAT AAC TTG GAG CGT TCG CAG  
 AGA CTT  
 ACA GAG  
 35 phe asn glu ala gly tyr lys ile leu gln ile lys ser asp ser ser leu  
 ile ser  
 ser lys leu tyr gln lys gly ile his lys asp asn leu glu arg ser gln  
 arg leu  
 thr glu  
 40 2674/841  
 2734/861

2704/851  
 2764/871

45 AGT GTG AAT ACG ATT CCC GAT AAT GCC ACC GCC ACC GCG GTG AGC AGC AGC  
 TCA CTC  
 ACC AAA TTC AAT ATA AAT TCA GCA AAG CCA GCC GCC GCC GCC GAT TCG CGT  
 AGC ACT  
 GGC ACA  
 ser val asn thr ile pro asp asn ala thr ala thr ala val ser ser ser  
 ser leu  
 50 thr lys phe asn ile asn ser ala lys pro ala ala ala ala asp ser arg  
 ser thr  
 gly thr  
 2794/881  
 2854/901

2824/891  
 2884/911

55 GAT CCA AGT ACA CCA CAG AAC ATT CTA CAG ATT AAA GAT TTG AAT TTC CCC  
 TCA AGG  
 TCG TCG TCT CGC ATA TCC CAG CCG GAG CTG CAC TAC GCC AGC CTA GAT CTT  
 CCC CAT  
 60 TGC AGT

asp pro ser thr pro gln asn ile leu gln ile lys asp leu asn phe pro  
ser arg  
ser ser ser arg ile ser gln pro glu leu his tyr ala ser leu asp leu  
pro his  
5 cys ser  
2914/921 2944/931  
2974/941 3004/951

GGC CAA AAT CCA GCT AAA TAC CTG AAG AGA GGA TCA CGC GAA TCG CCG CCG  
10 GTG TCC  
GCA TGC CCG GAG GAT GGG AAT ACC TAT GCG AAA ATC GAC TTT GAC CAA TCC  
GAC TCC  
TCT TCC  
gly gln asn pro ala lys tyr leu lys arg gly ser arg glu ser pro pro  
15 val ser  
ala cys pro glu asp gly asn thr tyr ala lys ile asp phe asp gln ser  
asp ser  
ser ser  
3034/961  
20 TCC TCA TCG AAC ATA TTT AAT ACG TAA  
ser ser ser asn ile phe asn thr OCH

3034/961

Table 2: Genomic DNA sequence

AGAACGACTTTTCTCCTTAGTCAGTCACAAGAAAACCTAAAGCTTACCA  
5 ACAATACGGCGTGTATTGTTAAATTATTACAACAAATAAAATATTCAAAT  
TGTATTTAAAAATATAGTAACCATTAATAAAATCAATATGCGAAAC  
TTTGTAATTTCTTACTCATCCTTGTGTTTTGAGCCCGCTTCTTAAGTTA  
AATCGTTAAATACCAGTTTAATCATTTTCATTGTCCTGATTTTCAGGAGCT  
AATTACATTTTAATCTTTGTATAAAATTCATAAAATTTAAATGGAAATGTT  
10 TAACCACATAAAATATTTGGGTATATAAAGTCGATACATACTTTTAAAT  
TTTGTTTCATACAAGAATATGGAAAGTAGATAATTTAGTTACCGATTAAA  
ACATTTCTAAAAATACAAAAAATTTAAAAATGATGATTAAATAAAAACTGT  
TATACTAAATTTAAACGAAACAAACGGTCATTTCGATAACTCAATTAGTAT  
CGAATAAGCCGGCGTGTAAATCGGGTTGGCAACTCTCACCAGGTGTAGAGA  
15 TCGGGATGGCAACTTCGTATTGTTATTCTATGCTGCGATAACGATAACA  
GCAAAGTGTTCATCGCAATAAATGTGGGTTTGATAATAAAGAATTGCGTT  
GGTGAACAATAATAACAAATGCTAAATGTATCGCGCGGATAACTAGTA  
AACACTGATTTTCGCGCATATCGGGCATAACGGGCAGCTAGACGCTTAGGT  
AACACATTTCCAGCCACATTGGCGTTGAGGTATTATTTCCCATATCCAT  
20 GTGCGTTTGTAATGATACCACCAGAGTGTGCCATATGTATCGTTGTTG  
TACATACATGCCTACGGGGAAAAATAACTCGCAGATACATATGTATGTAA  
GATGTATTAGAAATTCACAGATATATGTACATATAAATATATATATAT  
TTATGATGCTCATCTATAAAACAAAAATATGTACAAACATACGCGCGCACG  
TACTTATGTATGTACATATACATATATACATATATGTATAATAAAATGAG  
25 CATCTAGCTGCGGTTATCTTAATGCAATGCGCAGAAACCTGAAAACGAAA  
TAAACAATCTTTACAGCGCCAGCACAGTGAGCCAATTATGAATTCACAAT  
TCCACATCCAATTCCGATTCGGAATTCATCGCTTACATCCTAATTCTGA  
ATACGTCGCGCCGCGTAAGCTGCACTCGAATATTGACATAAACGACGTAA  
TTGCGTGTGTTGATTGCGATTTCCGATGCTCGATGTTGACAGACGGCAAG  
30 GATTTTTTTTGCCAGCCGACATTGCGAATGCTTTTCGCGTGTGCGTTG  
TGAAAAGCGAATTGTTTCCGGCAGTTGGAATGTTTTGTGCTGTTTAT  
GCTTAGAAAAAGCAAATGTATTGCACAAAACCTCGTGTTCCTACATTAGTA  
AAGCCTATAACTTAGGTATATGTTTCTAAATTACAATGCAAAAAATAAAA  
AACATTATACATGTGTTTCGTTCTTTAATTTGAAAACAGAAAAGTGAAAGC  
35 CTTGCAATCAAATATGTGTCCATATCGCCTACTAATAATATAAACACGT  
CGCCTTCCAGGAACCTAAGATTGGAATCATGGCATCAATATCGGATGACG  
GCATGGCGCTGAGTGGCTACCTCAAGAAGCTGAAGACCATGAAGAAGAAG  
TTCTTTGTGCTGTACGAGGAGACGAGCACTTCGGCAGCCCGGCTGGAGTA  
CTACGATACCGAAAAGAAGTTCTGCAAAGAGCCGAGCCAAAAAAGGTTA  
40 TCTATCTGAAGAATTGCTTCAACATCAATCGCCGTTTGGACACCAAGCAT  
AGATTTGTCATTGTGCTCTCCTCCAGAGACGGTGGATTTCGGCATCGTTCT  
CGAGAACGAAAATGATTTACGCAAATGGTTGGACAACTACTAGTTCTAC  
AAAGGAACATAGCCAATTCGAATGGAACAGCGCACTCACCTTATGGTATG  
CCAAATAAACTATAACTACCAGTTAGTATGAAACCTAAACACTTCATTTCT  
45 ACTTTGCAGACCACGTTTGGCAAGTTGTCATTCAAAAGAAGGGTATTTCTG  
GAGAAAGTTGGAATCACCGGAACCTACCACTGTTGCCTTACTTCAAAATC  
CCTGACATTCGTGTGCATTGGACCGGAGAAGACGCCCAATGGCGAGGATC  
GCGTTGCGAGCATTGAAATACTTTTGACCACGATCAGGCGGTTAGTTGTT  
GCCAGCAAACTGCAAGGGATTGTAAAATAATTTCGGACTTAATTTTCAGAT  
50 GCGGTCATGCATCCCAATGTATATTCTACGTGGAACCTGGCCGCCAA  
AGTGTCTTGGGATCTGGTGATCTGTGGATGGAGACGGATAACGCAGCTAT  
TGCTACTAATATGCACAACACGATACTGAGGTATTTAGCTCTCATTACAA  
CTAATCCAAGATTTTCATGATCATCCTACAAAACGACATAGATAGTTTAAG  
ATATCTCCAGTTAACTTTAATAATTCTGTGGGTTTTTTCTTTTCAGCGCT  
55 ATGTCAGCCAAAACAGAGTCGAACACGAATTTAATAAACGTTTATCAGAA  
CAGACCTGACTTAAGTCACGAGCCCATGAGAAAGCGATCGTCGTCTGCAA  
ACGAAGCATCGAAGCCGATAAACGTAAATGTCATACAAAATAGTCAAAAC

TCTCTCGAATTGCGCAGCTGCAGTTCGCCCCATAACTATGGTAAATACTT  
CAAATGTATGTTTAAACGCAAAATTAATCAAACGCAATCGTTTCAGGTTT  
CGGCAGAGAGAGATGCGATAGCTTACCAACCAGAAATGGAACCCTAAGCG  
AGTCCAGCAATCAAACGTACTTTGGTTCCAACCATGGACTGCGATCCAAT  
5 ACTATATCTGGCATCCGTCCGCACTCAACCAACAAGCATAGTAATAGTCC  
AACGTTCAACATGCCATTAAGATGCTCAGAATCCGAAGAGTCATCAATTA  
GTGTCGATGAATCCGACGACAACGGCAGTTTTAGCCACTACAGATTAAAG  
TGCCTTGCTATCAAATAATAATTATTTAATAATAATCACCATTTCATTTT  
CTAGCACGCGGTCTCTGAGACGGCAATTCCTGAGGAAAACATTGATGAC  
10 TTTGCCAGTGCGGAATTATTTAGCAAAGTCACCGAACAAAATGGTAAGCC  
AAACACAAAAACAATTTTTTAACATGAAAAGTAGCTAATCAATTGGCTTT  
GTTTAACTGCAGTAAAGTACGAAAACTACATACCGATGAATCCAGTCAAT  
CCTACCGATGCTATCCATGAAAAGGAGAAGGCTGATATGCAGAGATTGGA  
AGATGCTTCGCTGCATTTCACTTTCCGGAGCACGCGTCGGAAAAGCTTG  
15 CTAAGGATTTTGATCTGGACTCTGATAACCAGTGAGTACACATTTTCGCTT  
CAACTGTGCCACGTAATGCAATCAATCACATCTTGTTACAGATGCTGTCTG  
TCCCATTCGCGCCTATTTCGATAGGCAACAAGTTGAGCATTFAAAGTTTA  
ATAAGCGCTGGGACACTTGAATGATACGGGACAGAATCCGAATCGCGTG  
CGAGCCTACTCGGTTGGCTCCAAATCGAAGATACCGCGCTGCGACCTGCA  
20 GCGAGTGGTCTCTCGTGGAGGACAATAAACATGAGTTCACAGCGAATAGGA  
GTCAGAGTAGCATTACCAAGGAAGGAACCAGCTATGGCAGCAGTGCCAAT  
CGACAAAAGAAGTCCACAAGTGCTCCACTCCTCAGTCTGAAGAACCAGAT  
AAACTCCGACCGAATGAGTGACTTAATGGAAATTGATTTTTCACAAGCAA  
CCAATTTGGAAGAGCAGAAGTTCATCAAGAATAATGAAATTCGGAATAC  
25 ATTGAAAACGTGTTCCCAAAAGCCCCGCGAACGGATAGCTCCAGCCTAAC  
TCTGCACGCCACAAGTCAAAAGGACATTTTCAATGGCACCAAACTAAATA  
ACACTGCGATCACATCCGAGGATGGTTACCTCGAGATGAAGCCAGTCGGT  
AATGGATACACTCCAGTTTGAATTGCCTGCCAATGAAAGTGGAGAGGCT  
CAAGCTATCCGACTATCAGACAGCACCGCCAATCACCGCAACAGCCGCAC  
30 CAGTGACGATTTAAACAAAATTAGCACATACAATATATCCGCTGAGAAA  
TGGAGAGAACAGCCAGCAGAAGCGAGGAAAAGAAGTTCGAATTCGCCAT  
GAATGACAACACCTTTGGCTTGAAACCCACAAATGTCGAGAGTACAAGCA  
AAAGCCATGATGTTTCATTTCAGCAAATCAAATTGATTCCGAGAAAGTGTGC  
GCGCAGAGCAGCGATAAGCTAAATAATCTGGCCGACAAGATTGTGAGAA  
35 CAACAATTTGGATATAGGCGGGCATGAGGAAAAGAAGTTGGTTTCATTGCA  
TAAGCAGCGAAGACTACACACAAATCAAGGACAAATCGAATGATTTACACA  
AAATTTAACGAAGCCGGCTACAAAATTCTGCAAAATTAAGGCGACAGCTC  
ACTCATCTCATCGAAGCTATACCAAAAGGGTATACACAAGGATAACTTGG  
AGCGTTTCGAGAGACTTACGGAGAGTGTGAATACGATTCCCGATAATGCC  
40 ACCGCCACCGCGGTGAGCAGCAGCTCACTACCAAATTCAATATAAATTC  
AGCAAAGCCAGCCGCCCGCCGATTTCGCGTAGCACTGGCACAGATCCAA  
GTACACCACAGAACATTCTACAGATTAAAGATTTGAATTTCCCTCAAGG  
TCGTCTCTCGCATATCCAGCCGGAGCTGCACTACGCCAGCCTAGATCT  
TCCCCATTGCAAGTGCCAAAATCCAGCTAAATACCTGAAGAGAGGATCAC  
45 GCGAATCGCCCGCGGTGTCCGATGCCCCGGAGGATGGGAATACCTATGCG  
AAAATCGACTTTGACCAATCCGACTCCTCTCCTCCTCATCGAACATATT  
TAATACGTAAAGTTTTGAAATTTATGACCCTATCCTATATATATGATTTG  
TTTAATATTGTACATTTATTGTAAATATTCTCTGACAAGCAAAGCTTACA  
ATTTTGGATGCTAATAAAATAAATTTTATTTAAATTATAATGATCCCTTTG  
50 GACTTTTTTTTTTTTTTGGACTAAGAAATCACTACTAAAGAAGGGCTTTTC  
GAGGGTTAAA

Sequence similarity between CHICO and IRS1-4 is confined to the N-terminal region including the PH domain and the PTB domain. The amino acid identity is 41 percent in the PH domain and 38 percent in the PTB domain (Figure 3B and C). Although there is no significant overall homology within the C-terminal domain, the CHICO protein contains several putative SH2 binding motifs characteristic for IRS family members. Two motifs at positions 411 and 641 fit the consensus binding site (YXXM) for the p85/p60 adaptor subunit of P110 PI(3)K (Songyang et al., 1993; Weinkove et al., 1997) and one (at position 243) corresponds to the consensus (YXN) for GRB2/DRK binding (Olivier et al., 1993; Songyang et al., 1993).

Owing to the insertion of the P element 80 bp downstream of the translation start site *chico*<sup>1</sup> is likely to be a null mutation. The *chico*<sup>2</sup> allele is a synthetic deletion allele covering the putative translation start site and the regulatory region of *chico* (Figure 3A; see experimental procedures). Flies homozygous for this synthetic *chico* null allele were viable and showed phenotypes indistinguishable from flies homozygous for *chico*<sup>1</sup> (Figure 1B). The mutant phenotype of both alleles is fully rescued by an 8 kb genomic rescue construct encompassing the *chico* transcription unit and its endogenous regulatory sequences (Figure 3A). Therefore the reduction in body size and the female sterility is caused by the loss of *chico* function.

In order to profit from the close similarity of *chico* with IRS 1-4, clearly detectable, and preferably quantifiably differences between *chico* mutants and wild-type flies must exist.

Therefore, specific differences have been searched for and studied.

To quantify size differences in various mutants, the weight of individual flies was determined (Figure 1B). Flies homozygous for the P element (*chico*<sup>1</sup>)

or a synthetic *chico* deletion (*chico*<sup>2</sup>) have a drastic weight reduction (by 65% in females and 55% in males) compared with wild-type control flies of the same age. Body size reduction is observed at all developmental stages, but does not alter the overall proportions of the flies (Figure 1A).

Since the reduction in body and organ size in *chico* mutants could be due to a reduction in the number of cells and/or a reduction in the size of the individual cells, cell number and cell size in the wing was determined. In the wing, each epithelial cell secretes cuticle with a single hair, so that counting the number of hairs and determining their density provides a direct measure of cell number and cell size in the wing. (See Table 3)

**Table 3: Cell Size and Cell Number are Affected in Wings of Homozygous Mutan Animals<sup>a</sup>**

Genotype	1 Area <sup>b,c</sup> (10 <sup>6</sup> μm <sup>2</sup> )	2 Overall size reduction (%)	3 Cell density <sup>d</sup> (cells/μm <sup>2</sup> )	4 Area covered per cell <sup>e</sup> (μm <sup>2</sup> )	5 Cell size reduction (%)	6 Approx. No. of cells in measu- red area <sup>b,f</sup>	7 Cell number reduction (%)
Y,W; +/Sp	1.47±0.009	-----	6.38x10 <sup>-3</sup> ±0.1x10 <sup>-3</sup>	157±2.36	-----	9379	-----
Y,W; chico <sup>2</sup> /Sp	1.40±0.018	4.8	6.32x10 <sup>-3</sup> ±0.1x10 <sup>-3</sup>	158±2.90	0	8848	5.7
Y,W; chico <sup>2</sup> /	0.89±0.009	39.5	7.70x10 <sup>-3</sup> ±0.1x10 <sup>-3</sup>	130±1.66	17.2	6853	27
chico <sup>2</sup>							

<sup>a</sup> From females at least eight wings of each genotype were analyzed.

<sup>b</sup> The area of the whole wing was integrated exclusive the alula and the costal cell.

<sup>c</sup> Measured using NIH Image 1.60.

<sup>d</sup> Assessed by counting number of wing hairs on the dorsal wing surface in a 10 000 μm<sup>2</sup> area just posterior to the PCV.

<sup>e</sup> Reciprocal of column 3.

<sup>f</sup> Generated by multiplying the values in column 1 by those in column 3.

As shown in Table 3, the 40 percent reduction in the size of *chico* mutant wings is caused by a reduction in both cell number and cell size. Reduction in cell number accounts for 68 percent of the total reduction in wing size. The remaining 32 percent of the reduction in wing size is due to a reduction in the average size of mutant cells. Similar results were obtained for the eye. It could be shown that in homozygous mutant *chico* flies, ommatidial number is reduced by approximately 40 percent: homozygous *chico* flies have only about 480 ommatidia per eye (Table 4) whereas wild-type flies have approximately 780 ommatidia per eye. Therefore, loss of *chico* function reduces body size by means of reducing cell number and cell size.

To test whether the reduction in the size of *chico* mutant cells is also observed during larval stages third instar wing discs of larvae homozygous or heterozygous for *chico* were dissociated and the relative cell size of the two cell populations was determined by FACS analysis (Figures 2A to 2C). A 10-14 percent reduction in the mean of the forward scatter of homozygous *chico* cells compared with heterozygous cells indicates that the size of *chico* imaginal disc cells is also reduced.

Since the effect of loss of *chico* function on the overall body and organ size could be due to a non-autonomous role of *chico* in humoral growth regulation or to an autonomous role in a tissue and cell type specific manner, the autonomy of *chico* was investigated. To test the cell autonomy of the *chico* mutation, clones of genetically marked homozygous mutant *chico* cells in a heterozygous background in the eye were generated (Figure 4A) using the *hs-FLP/FRT* system (Xu and Rubin, 1993). In each ommatidium, the R1-R6 photoreceptor cells are arranged in an asymmetric trapezoid. The tall side of the trapezoid is formed by photoreceptors R1-R3 facing



anteriorly. The centrally located R7 photoreceptor has a smaller rhabdomere than the six outer cells. Each of these morphological characteristics is retained in *chico* mutant ommatidia. Thus, loss of *chico* function does not  
5 impair the specification of cell fate. However, it is striking that the size of each mutant photoreceptor and hence the entire ommatidial unit in the mutant clone, is reduced by more than 50 percent. On the periphery of the clones of homozygous mutant tissue, ommatidia consist of  
10 homozygous and heterozygous cells. The genotype of each photoreceptor can be assessed by the presence or absence of red pigment. Small homozygous mutant photoreceptor cells (arrowheads in Figure 4A) coexist with heterozygous cells in the same ommatidium. Remarkably, this does not  
15 significantly alter the shape of the ommatidia and the arrangement of the photoreceptors. Autonomy of cell size control is also observed in the wing (data not shown). Therefore, final cell size is autonomously dependent on *chico* function in each individual cell.

20 In order to further study the effects of *chico*, it was tested whether *chico* affects the size of organs and body parts autonomously. For this testing, *chico* function was selectively removed in the eye imaginal disc using the *eye-FLP* technique (see Example  
25 4). The results presented here, show that selected removal of *chico* function in the head using the *eye-FLP* technique reduces head size. This reduced head size phenotype can be used to identify mutations in other genes that affect growth and thus are likely to encode  
30 components of the insulin signalling pathway. These mutations thus identify genes that are potential drug targets for human diseases such as type-2 diabetes. The eye imaginal disc gives rise to the compound eye and the head capsule but not to the proboscis. In embryos  
35 heterozygous for *chico*, mitotic recombination was selectively induced in the eye progenitor cells by using an FLP recombinase driven by the *eyeless*-enhancer

(Quiring et al., 1994). Owing to the presence of a recessive mutation affecting cell survival on the *chico*<sup>+</sup> chromosome, *chico* homozygous mutant cells have a proliferative advantage and contribute to the majority of  
5 cells in the eye and the head. Thus flies have heads that are largely homozygous for *chico* while the rest of the body is heterozygous. In such flies, the eyes and the head capsule are strongly reduced in size while the proboscis and the rest of the body are of wild-type size  
10 (Figure 4B, C). Thus *chico* acts autonomously in the control of cell size and organ size.

It was furthermore investigated whether the reduction in cell number caused by the absence of *chico* function is the result of a prolonged cell cycle time or  
15 of an increased rate of apoptosis during development. In order to analyze the behavior of *chico* mutant cells during development, genetically marked homozygous mutant cells were generated by mitotic recombination. This allowed comparison between the behavior of homozygous  
20 mutant clones and their wild-type sister clones, called twin spots, generated during mitotic recombination. Three differences between mutant and wild-type twin clones are obvious: first, *chico* mutant clones are rare: in approximately 90 percent of the clones, only the darkly  
25 pigmented wild-type twin spot can be detected. This is most likely due to the fact that small mutant clones encompass only a few ommatidia and escape detection. Secondly, when a non-pigmented mutant clone is detected, the clone is variable in size and often significantly  
30 smaller than the wild-type sister clone. Thirdly, there are regional differences in the frequency of mutant clones: clones are more frequently observed in the anterior half of the eye around the equator. The equator defines a line of dorso-ventral mirror image symmetry in  
35 the orientation of the ommatidial units. It appears that mutant cells have a better chance to grow or survive in the center of the eye than on its periphery. The behavior

of *chico* mutant clones is similar to that of *M* mutant clones and has been described as cell competition (Morata and Ripoll, 1975; Simpson, 1979). It indicates that the development of *chico* mutant cells is selectively impaired compared with wild-type cells and that there are regional differences in the ability of mutant cells to grow or survive.

In addition, mutant clones in the eye and wing imaginal discs were tested to investigate whether the reduced size of *chico* mutant clones observed in the adult is due to a growth disadvantage or to impaired cell survival during the final stages of differentiation. This investigation was performed on eye imaginal discs containing *chico* mutant or wild-type control clones, marked by the absence of the green *arm-lacZ* staining, and their intensely bright green staining twin spots. As seen in the adult, the mutant clones are smaller than their twin spots and are variable in size. The clones often form a thin line. The fact that *chico* mutant clones in the third instar disc and in the adult eye exhibit a similar behavior argues against the possibility that homozygous mutant *chico* cells are eliminated during differentiation in the pupal stage.

As a critical determinant of organ size through counterbalancing cell proliferation, apoptosis has been postulated (Conlon and Raff, 1999). In order to test whether programmed cell death contributes to size control by reducing cell number, discs containing either *chico* mutant clones or wild-type control clones were analyzed by terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labelling (TUNEL). No significant difference in occurrence of apoptotic cells between wild-type and mutant clones was detected (data not shown). Since *chico* mutant clones are rather small, mutant clones in a *Minute* background were induced. Even though such clones were greatly enlarged due to their growth advantage they also did not reveal enhanced

apoptosis compared with wild-type control clones in a Minute background (data not shown). Furthermore, no increase in morphological signs of programmed cell death such as enlarged cells or cells with picnotic nuclei in *chico* mutant clones was observed, neither in the imaginal discs nor in the adult eye. These results are also consistent with the FACS analysis of heterozygous and homozygous *chico* mutant wing disc cells. No significant difference in the apoptotic sub-G1 fraction of homozygous *chico* mutant cells compared with heterozygous cells was detected (data not shown). Therefore, these results show that *chico* function is not necessary for cell survival, but is required for cell growth and cell proliferation throughout development. Homozygous *chico* mutant cells have a selective growth disadvantage: they grow more slowly than wild-type cells, as indicated by their underrepresentation in discs and in the adult eye, and they cannot reach the normal size of wild-type cells. The cell cycle profiles of heterozygous and homozygous *chico* mutant wing disc cells, however, are similar (data not shown) suggesting that the increased cell cycle time of *chico* mutant cells is caused by proportional expansion of the G1, S and G2 phase of the cell cycle.

It was also found that *chico* interacts with other essential compounds. Such compounds with which *chico* genetically interacts are the Drosophila insulin receptor and *PI(3)kinase*. Due to the found homology of CHICO with mammalian IRS1-4, genetic interactions with other components involved in signaling via IRS proteins, such as the insulin receptor and the p110 PI3kinase (PI3K), can be studied. Loss of function mutations in *Inr* are lethal but certain heteroallelic combinations survive to adulthood. Such *Inr* mutant flies are reduced in size (Chen et al., 1996). It was found that, like in *chico* mutants, cell size is reduced by 28 percent in *Inr*<sup>313</sup>/*Inr*<sup>327</sup> flies. Furthermore targeted expression of a dominant negative variant of Drosophila p110 PI3K in the

developing eye or wing causes a reduction in cell size in the eye, and in both cell size and cell number in the wing. Conversely, overexpression of a constitutively active, membrane-targeted version of PI3K increases cell size and cell number (Leevers et al., 1996). In flies that are homozygous for *chico*, heterozygosity for a hypomorphic *Inr* allele led to a further reduction in cell number in the wing and the eye (see Table 4).

10

15

**Table 4:** One Mutant Copy of the *Inr* Enhances the Growth Phenotype of *chico* Mutant Cells

Wing Analysis <sup>a</sup>						
Genotype	Area <sup>b,c</sup> (10 <sup>6</sup> µm <sup>2</sup> )	Overall size reduction (%)	Cell density <sup>d</sup> (cells/µm <sup>2</sup> )	Area covered per cell <sup>e</sup> (µm <sup>2</sup> )	Cell size reduction (%)	Approx. No. of cells in measured area <sup>b,f</sup>
<i>chico</i> <sup>2</sup> ;+/+	0.96±0.03	-----	8.0x10 <sup>-3</sup> ±0.12x10 <sup>-3</sup>	125±1.9	-----	7680
<i>chico</i> <sup>2</sup> ; <i>Inr</i> <sup>05545</sup> /+	0.79±0.03	17.7	7.8x10 <sup>-3</sup> ±0.09x10 <sup>-3</sup>	128±1.5	0	6162
Cell number reduction (%)						19.8
Eye Analysis <sup>g</sup>						
Genotype	Eye area <sup>c</sup>	No. of ommatidia per eye	Area covered per ommatidium <sup>h</sup> (arbitrary units)			
<i>chico</i> <sup>2</sup> ;+/+	261 896±5097	483±7	542			
<i>chico</i> <sup>2</sup> ; <i>Inr</i> <sup>05545</sup> /+	198 634±3280	411±2	483			

<sup>a</sup> From females four wings of each genotype were analyzed.<sup>b</sup> The area of the whole wing was integrated exclusive the alula and the costal cell.<sup>c</sup> Measured using NIH Image 1.60.<sup>d</sup> Assessed by counting number of wing hairs on the dorsal wing surface in a 10 000 µm<sup>2</sup> area just anterior to the PCV.<sup>e</sup> Reciprocal of column 3.<sup>f</sup> Generated by multiplying the values in column 1 by those in column 3.<sup>g</sup> Eight eyes of each genotype were analyzed.<sup>h</sup> Generated by dividing the values in column 1 by those in column 2.

Thus, in the absence of *chico* function a reduction of the receptor level potentiates the growth reduction. This CHICO independent signaling of INR is likely to be mediated by PI3K binding sites in the C-terminal tail of the INR (Yenush et al., 1996, see discussion). Similarly, expressing a catalytically inactive version of PI3K in *chico* homozygous wing discs leads to a further reduction in wing size by 48 percent (data not shown). Thus the *chico* mutant phenotype is modified by mutations in *Inr* and *PI3K*. This is consistent with the notion that INR, CHICO and PI3K form a conserved signaling pathway involved in the cell autonomous control of growth and cell size in *Drosophila*.

Besides of its influence on cell size and cell number, it was found that CHICO also controls lipid levels. This finding is further evidence on the relevance of *chico* in the insulin signalling pathway, since said pathway is known for its role in the control of cellular metabolism in vertebrates and in *C. elegans*. Thus it was investigated whether energy stores are altered in *chico* mutant flies. The fresh and dry weights of different flies were determined (Figure 5A) as well as their amounts of lipid, protein and glycogen per unit of fresh weight (Figure 5B). While there was no significant difference in levels of proteins and glycogen, lipid levels were increased significantly in *chico* males (Figure 5B). In fact, in spite of their smaller size, *chico* males had almost twice as much lipids as wild-type males per mg fresh weight. The dramatic increase in lipids in *chico* mutant males is reminiscent of hypertriglyceridemia in IRS-1 deficient mice (Abe et al., 1998) and of fat accumulation observed in *C. elegans* containing a mutation in the *daf-2* gene, which encodes the insulin receptor homologue (Kimura et al., 1997). Thus it appears that the INR signaling pathway controls cellular metabolism in vertebrates, nematodes and insects.

Since it could be shown that loss of function mutations in *chico*, which encodes a Drosophila homolog of IRS 1-4, cause a reduction in overall growth by reducing cell size and cell number, since it could furthermore be shown that the primary function of CHICO is to regulate overall growth by coordinating the control of cell cycle progression and cell growth and not by controlling apoptosis, and since CHICO furthermore is likely to be part of a nutritional sensing system, *chico* and its mutations are very useful tools for the investigation of e.g. the insulin signalling pathway, the screening of potential drugs for the treatment of defects in said pathway, and the screening of drug targets. *Chico* and its mutants are especially suitable tools in Drosophila mutants usable as in vitro monitoring systems.

Thus, one subject of the present invention is a method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size and/or cell size and/or development time and/or lipid level is determined whereby alterations of the body size and/or cell size and/or development time and/or lipid level are detectable in at least part of the animal. In a preferred embodiment said method is a method for searching for compounds or mutations interacting directly or indirectly with CHICO involving life processes, whereby a viable *chico* mutant insect, e.g. a fly such as Drosophila, is treated with at least one compound or with at least one compound generating means, and that the effect of such treatment is detected, whereby said mutant comprises at most one wild-type *chico* gene. As already mentioned above, the animals suitable in the scope of the present invention are insects. The advantage of insects is the highly conserved insulin signaling pathway together with their



fast reproducibility. Preferably said method is performed with a *Drosophila* mutant, whereby said mutant is treated in the egg or larvae stadium with said compound or compound generating means. As was shown above, different  
5 easily detectable and also quite well quantifiable characteristics can be used to determine the effect of an applied treatment, such as alteration in size and/or weight and/or developmental time and/or lipid levels Of course, for many applications it is desirable that the  
10 animals used are already altered in size and/or weight and/or developmental time and/or lipid levels, so that therapeutical effects can be detected.

Mutants suitable for the method of the present invention are such ones that do not comprise a  
15 wild-type *chico* gene or that have one wild type *chico* gene. Thus the following combinations are encompassed by the present invention:

- both *chico* genes are totally lost,
- both wild-type *chico* genes are replaced by  
20 *chico* alleles with reduced CHICO activity
- both wild-type *chico* genes are replaced by *chico* alleles with no CHICO activity,
- one *chico* gene is totally lacking and one is replaced with a *chico* allele having no CHICO activity,
- 25 - one *chico* gene is totally lacking and one is replaced with a *chico* allele having reduced CHICO activity,
- one *chico* allele has no activity and one *chico* allele has reduced activity,
- 30 - one *chico* is the wild-type *chico* gene, and the second *chico* is an allele with no activity
- one *chico* is the wild-type *chico* gene, and the second *chico* is an allele with reduced CHICO activity
- one *chico* is the wild-type *chico* gene, and  
35 the second *chico* is totally lacking.

As wild-type CHICO in the scope of the present invention any protein is meant that has the same

effect as wild-type CHICO and at least about 50 % identity with the protein structure of Table 1. As wild-type *chico* any *chico* gene is referred to that encodes the amino acid sequence of Table 1 (2, 3), or that encode a protein which is sufficiently homologous to CHICO that it has the same effect in the animals of the present invention as CHICO. Relevant effects of CHICO - as it results from the above disclosure - are cell size, cell number and lipid level. Preferred DNA sequences are e.g. the genomic or the cDNA sequence represented in Table 2 (SEQ. ID. NO. 4) or Table 1 (SEQ. ID. No. 1, 2).

As *chico* mutation according to the present invention any mutation is considered that has an at least reduced activity compared to the activity of the wild type animal. Preferred *chico* mutations are those having no activity and leading to size reduced homozygous animals. Such *chico* mutations are the sequences resulting in a cell number reduction of at least 10 %, preferably at least 30 %, a cell size reduction of at least about 10 %, preferably at least about 30 %, and an enhancement of the lipid content per weight unit of at least about 20 %, preferably about 50 % (all % concerning homozygous *chico* mutant animals in comparison with wild-type animals). Preferred examples for such a mutation are the mutations described as *chico*<sup>1</sup> and *chico*<sup>2</sup>.

In general, total loss of *chico* activity is obtained when e.g. at least the PH domain is deleted or tyrosin residues Tyr(411) and Tyr(641) (positions referred to SEQ ID NOS 2 and 3) are substituted. Partial loss of CHICO activity is e.g. due to substitutions in the region of the PTB domain. The above mentioned alterations in *chico* are by no means complete and have to be clearly understood as non limiting examples.

The animals of the present invention can e.g. be obtained by mutagenesis procedures known to the expert. Suitable mutagens include but are not limited to P-elements, X-ray and ethylmethane sulfonate (EMS).

A suitable method for generating mutant insects comprises that adult insects, in particular males, are treated with a mutation generating means under mutation generating conditions, that thus treated insects  
5 are crossed to wild-type or mutant insects, in particular to *chico* mutant insects, and that viable offsprings with altered cell number and /or cell size and/or developmental time and/or lipid levels are cultivated under suitable conditions.

10 As it has been shown in the scope of the present invention, it is not necessary to generate fully mutant animals. By e.g. the eye-FLP technique, it is possible to selectively generate mutated head regions. Such partially mutated animals are advantageous for many  
15 applications, since they avoid the laborous need to generate mutated strains.

Specific and much preferred applications of the animals and the method of the present invention are the screening for compounds that are useful in the  
20 modulation, e.g. the treatment, of diabetes type 2, and the further investigation of diabetes type 2, in particular the search for further factors involved in the development of said disease. Such factors possibly involved in the development of said (but also other)  
25 disease can be found by applying a mutation generating means, in particular a mutagen such as radiation, P element, or chemical compound, to the animal under conditions suitable to generate gene defects in the factors

30 One very interesting application of *chico* mutant insects or insects with *chico* phenotype is connected with the fact that the insulin signaling pathway is conserved in structure and function. In mammalian cells, activation of the insulin or IGF-1  
35 (insulin-like-growth factor-1) receptor by insulin and IGF-1, respectively, results in the recruitment of IRS-1 or IRS-2 to the receptor via interaction of the IRS PTB

domains with a phosphotyrosine motif (NPXY) in the juxtamembrane region of the receptors. Phosphorylation of multiple tyrosine residues of IRS-1 triggers the activation of various signaling pathways including the

5 RAS/MAP kinase pathway via the SH2/SH3 adaptor GRB2, and the PI3K/PKB pathway via the p85 SH2 adaptor subunit of p110 PI3K (Yenush and White, 1997). The Drosophila INR shares many structural features with its human homologues, including its heterotetrameric structure and

10 a conserved PTB consensus binding site in the juxtamembrane region. Although, the Drosophila INR contains a 400 amino acid C-terminal extension not found in any of the vertebrate receptors, it is nevertheless an important tool not only for screening compounds

15 activating the insulin signalling pathway, but also for finding and/or further investigating compounds that are also members of said pathway. However, also the C terminal extension is of importance. This C-terminal tail contains three YXXM consensus binding sites for the SH2

20 domain of the p60 subunit of PI3K and four additional NPXY consensus PTB binding sites. The C-terminal domain is functional, since expression of a chimeric receptor consisting of the extracellular domain of the human INR and the intracellular domain of the Drosophila INR in

25 murine 32D cells lacking endogenous IRS-1 can partially activate mammalian PI3K and S6K. In contrast, the ability of the human INR to activate PI3K in this system is strictly dependent on the coexpression of IRS-1 (Yenush et al., 1996). These findings and the identification of

30 CHICO suggest that in e.g. Drosophila INR couples to the downstream effector PI3K in two different ways, one using docking sites in the INR C-terminal tail and the other connecting through docking sites in CHICO.

As described here, the effects on growth and

35 cell size of *chico* mutants are remarkably similar to the phenotypes of mutations in genes encoding other components of the INR pathway in e.g. Drosophila.

Although loss of function mutations in the *Drosophila* *INR* gene are lethal, certain heteroallelic combinations are viable and show delayed development, reduced body size and decreased cell number (Chen et al., 1996) and cell size (this application). Expression of dominant negative or constitutively active variants of p110 PI3K in the developing wing and eye reduces or increases cell number and cell size, respectively (Leevers et al., 1996). Furthermore viable mutations in the gene encoding *Drosophila* Protein Kinase B (Staveley et al., 1998) cause a reduction in cell number and cell size (H.S. and E.H., unpublished results). The striking similarities between the phenotypes of *chico* and mutations in the genes encoding *INR* and *DPKB*, as well as the genetic interactions between mutations in *Inr*, *chico* and *PI3K*, show the specific role of the *INR* pathway in control of cell growth and cell number as a process independent of pattern formation and makes not only flies with a *chico* mutation induced phenotype a valuable in vivo monitoring system, but also flies with a *chico* mutation and at least one further mutation as described above.

Thus, the *chico* mutant animals of the present invention are an especially useful tool to investigate the insulin signaling pathway and possible pharmaceuticals to overcome defects therein, since said pathway is highly conserved from vertebrates to *Drosophila*, not only in regard to its structure but also to its function.

### Examples

#### Example 1: *Drosophila* strains

*chico*<sup>1</sup> is a P element insertion allele, originally called *fs(2)4*<sup>1</sup> (Berg and Spradling, 1991). The P element was mapped using standard PCR with primers specific to the 3' end of the P element and to the

genomic sequence. Subsequently, the insertion site was precisely determined by sequencing the amplified PCR fragment. *chico*<sup>2</sup> was derived from *chico*<sup>1</sup> by mobilizing the P element. The resulting *Df(2L)flp147E* deletes the translation start site and the regulatory region of *chico* and the 3' coding sequences of *bsk*. The *bsk* mutation was complemented by insertion of a *bsk* rescue construct on the *Df(2L)flp147E* chromosome (Riesgo et al. 1996). For genetic interaction analysis we used *Dp110<sup>D954A</sup>*, a dominant negative form of p110 of *Drosophila* PI3K (Leevers et al., 1996) and *Inr<sup>05545</sup>*, a P element induced hypomorphic allele (Fernandez et al., 1995). The *Dp110<sup>D954A</sup>* transgene was driven by GAL4 which was expressed in the dorsal wing pouch using the MS-1096 line (Capdevila and Guerrero, 1994). The *Inr* allele is hypomorphic and recessive lethal.

#### Example 2: Molecular characterization of *chico*

An 11 kb genomic DNA fragment which has been described in Riesgo-Escovar et al., 1996 and encompasses the Jun kinase (*bsk*) and *chico* transcription units was used to screen a *Drosophila* cDNA library. From this screen, a partial cDNA (U1) for *chico* was recovered, sequenced, and used to screen an embryonic *Drosophila* cDNA library. Several cDNAs were isolated and partially sequenced (U2-U4). Sequence search of the *Drosophila* EST database with these sequences identified the EST GH02661. Sequencing of this EST clone indicated that it represents a full-length *chico* transcript that contains a consensus sequence for translation initiation (Cavener, 1987) and ends with a poly A tail 15 bp after a consensus poly-A addition signal. All cDNAs were found to encode the same transcript. The 11 kb genomic region was fully sequenced to establish the exon/intron structure of *chico*, and also its position in relation to *bsk* and *ME31B*. From a genomic phage of the region, a BamHI/ BamHI fragment was

subcloned into pBluescript, and a resection from the *bsk* side was performed to generate a 9.5 kb fragment that was subcloned into a transformation vector and used to generate a genomic rescue construct for *chico*. pWAX (described in Riesgo-Escovar et al., 1996) rescued both the phenotypes of *chico* and *bsk* separately and in a double mutant (data not shown, and Riesgo-Escovar et al., 1996).

### 10                    **Example 3: Weight Analysis**

Body weight of individual male and female flies (n = 20) was measured with a precision scale (range 0.001 - 10 mg; Mettler ME30). Flies were reared under the same growth conditions and were age-matched (two days old) before weighing. The genotypes analyzed were the following: *y w; +/+*, *y w; chico<sup>2</sup>/+* (heterozygotes for the synthetic null allele), *y w; chico<sup>2</sup>/chico<sup>2</sup>*, *y w; chico<sup>1</sup>/+* (heterozygotes for the P element insertion allele), *y w; chico<sup>1</sup>/chico<sup>1</sup>* and *y w; chico<sup>1</sup>/chico<sup>2</sup>*.

### 20                    **Example 4: Clonal Analysis**

*chico<sup>1</sup>* was recombined onto the FRT40 chromosome (Xu and Rubin, 1993).

Germline clones of the *chico<sup>1</sup>* allele were generated using the autosomal dominant female-sterile technique in combination with the Flp recombinase system (Chou and Perrimon, 1996). Females of the genotype *y w; chico<sup>1</sup>, FRT40/CyO y<sup>+</sup>* were crossed with *y w hsFlp/Y; P(ovo<sup>D1</sup> w<sup>+</sup>) FRT40/CyO* males. Early third instar larvae were heat-shocked for 1.5 hr at 38°C. Females of the genotype *y w hsFlp/y w; chico<sup>1</sup> FRT40/P(ovo<sup>D1</sup> w<sup>+</sup>) FRT40* were selected and crossed to *chico<sup>1</sup>/CyO y<sup>+</sup>* males. The resulting progeny lacking any zygotic *chico* function and their siblings bearing the *CyO y<sup>+</sup>* chromosome were analyzed.

For the generation of clones in the adult eye larvae of the genotype *y w hsFlp; chico<sup>1</sup> FRT40/ w<sup>+</sup> FRT40*

were subjected to a heat shock 24 - 48 hr AED for 1 hr at 37°C to induce mitotic recombination. Adults were examined for w clones and their corresponding twin spots (red pigmented) in the eye. Histological sections of the eyes were done as described previously (Basler and Hafen, 1988). Selective removal of *chico* function in the eye disc progenitors was achieved in animals of the genotype *y w ey-Flp; chico<sup>1</sup> FRT40 / P(w<sup>+</sup>) 1(2)2L-3.1 FRT40* and *y w ey-Flp; chico<sup>1</sup> FRT40 / P(w<sup>+</sup>) 1(2)2L-3.1 FRT40; P(w<sup>+</sup> *chico* genomic rescue construct *pCSR4*)/+.* The *eyFlp* technique has been developed by B. Dickson (personal communication).

Wing clones. Larvae of the genotype *f hsFlp/f; chico<sup>1</sup> FRT40/ck P(f<sup>+</sup>) FRT40* were subjected to a heat shock 48 - 72 hr AED for 0.5 hr at 36°C to induce mitotic recombination. Wings were mounted and examined under a compound microscope.

Disc clones. Larvae of the genotype *y w hsFlp/y w; chico<sup>1</sup> FRT40/P(arm-lacZ w<sup>+</sup>) FRT 40* and *y w hsFlp/y w; FRT40/P(arm-lacZ w<sup>+</sup>) FRT40*, respectively were subjected to a heat shock 24 -48 hr AED for 0.5 hr at 32°C to induce mitotic recombination at a low frequency. Larvae at late third instar stage were dissected. Discs were fixed and permeabilized and stained with appropriate antibodies. Antibodies were: rabbit anti-β-Gal (1/2000) and FITC- or TR-conjugated secondary antibodies (1/200). Actin filaments were stained using phalloidin-TR (Molecular Probes).

#### Example 5: TUNEL Assay

Apoptotic cells were detected using the ApopTag system (ONCOR). Clones in larvae of the genotype *y w hsFlp/y w; chico<sup>1</sup> FRT40/P(arm-lacZ w<sup>+</sup>) FRT 40* and *y w hsFlp/y w; FRT40/P(arm-lacZ w<sup>+</sup>) FRT40*, respectively, and *y w hsFlp/y w; chico<sup>1</sup> FRT40/P(arm-lacZ w<sup>+</sup>) M(2L)Z FRT 40* and *y w hsFlp/y w; FRT40/P(arm-lacZ w<sup>+</sup>) M(2L)Z FRT40*, respectively, were induced as described above. Larvae at



late third instar stage were dissected. Discs were fixed and stained as described above. 3'-OH ends of DNA were labelled for 0.5 hr at 37°C by addition of digoxigenin 11-UTPs by the enzyme TdT and subsequently detected with  
5 FITC-conjugated anti-digoxigenin antibody. Discs of *GMR-grim* larvae, kindly provided by John Abrams (University of Texas), were used as positive controls.

#### Example 6: Flow Cytometry

10 Female larvae of the genotype *chico*<sup>2</sup>/+ and *chico*<sup>2</sup>/*chico*<sup>2</sup>, respectively, were dissected at late third instar stage (non-wandering stage). Dissociation of wing discs was done as described in Neufeld et al., 1998. Approximately 20 discs were dissociated. The cell  
15 suspension was analyzed using a Becton Dickinson FACStar<sup>Plus</sup> and the data was analyzed using Cell Quest (Becton Dickinson).

#### Example 7: Metabolic Studies

20 Adult males (n = 10) of the genotypes *chico*<sup>2</sup>/*chico*<sup>2</sup>, *chico*<sup>2</sup>/+ and +/+ were collected 3 days after eclosion. The fresh and dry weight, respectively, from individual males was determined. To determine the dry weight, males were fixed in 100% ethanol for 10  
25 minutes at 90°C and then dried for 2 hr at 110°C. Protein data were obtained through Kjeldahl digestion and subsequent Nesslerization (Minari and Zliversmit, 1963), with total nitrogen converted to protein by using a factor of 6.25. Glycogen and lipid data were obtained as  
30 described in van Handel and Day, 1988.

While there are shown and described presently preferred embodiments of the invention, it is to be distinctly understood that the invention is not limited  
35 thereto but may be otherwise variously embodied and practiced within the scope of the following claims.

Literature

- 5 Abe, H., Yamada, N., Kamata, K., Kuwaki, T., Shimada, M.,  
Osuga, J., Shionoiri, F., Yahagi, N., Kadowaki, T.,  
Tamemoto, H., Ishibashi, S., Yazaki, Y., and Makuuchi, M.  
(1998). Hypertension, hypertriglyceridemia, and impaired  
endothelium-dependent vascular relaxation in mice lacking  
10 insulin receptor substrate-1. *J. Clin. Invest.* 101, 1784-  
1788.
- Basler, K. and Hafen, E. (1988). Control of  
photoreceptor cell fate by the sevenless protein requires  
a functional tyrosine kinase domain. *Cell* 54, 299-312.
- 15 Berg, C. A. and Spradling, A. C. (1991). Studies on the  
rate and site-specificity of P-element transposition.  
*Genetics* 127, 515-524.
- 20 Bryant, P. J. and Simpson, P. (1984). Intrinsic and  
extrinsic control of growth in developing organs.  
*Quarterly Review of Biology* 59, 387-415.
- Capdevila, J. and Guerrero, I. (1994). Targeted  
25 expression of the signaling molecule decapentaplegic  
induces pattern duplications and growth alterations in  
*Drosophila* wings. *EMBO J.* 13, 4459-4468.
- Cavener, D. R. (1987). Comparison of the consensus  
30 sequence flanking translational start sites in *Drosophila*  
and vertebrates. *Nucl. Acids Res.* 15, 1353-1361.
- Chen, C., Jack, J., and Garofalo, R. S. (1996). The  
*Drosophila* insulin receptor is required for normal  
35 growth. *Endocrinology* 137, 846-856.
- Chou, T. B. and Perrimon, N. (1996). The autosomal FLP-  
DFS technique for generating germline mosaics in  
*Drosophila melanogaster*. *Genetics* 144, 1673-1679.
- 40 Conlon, I. and Raff, M. (1999). Size control in animal  
development. *Cell* 96, 235-244.
- de Valoir, T., Tucker, M. A., Belikoff, E. J., Camp, L.  
45 A., Bolduc, C., and Beckingham, K. (1991). A second  
maternally expressed *Drosophila* gene encodes a putative  
RNA helicase of the "DEAD box" family. *Proc. Natl. Acad.  
Sci. USA* 88, 2113-2117.

- Edgar, B. A., Lehman, D. A., and O'Farrell, P. H. (1994).  
Transcriptional regulation of string (*cdc25*): A link  
between developmental programming and the cell cycle.  
5 *Development* 120, 3131-3143.
- Fernandez, R., Tabarini, D., Azpiazu, N., Frasch, M., and  
Schlessinger, J. (1995). The *Drosophila* insulin receptor  
homolog: a gene essential for embryonic development  
10 encodes two receptor isoforms with different signaling  
potential. *EMBO J.* 14, 3373-3384.
- Gallant, P., Shio, Y., Cheng, P. F., Parkhurst, S. M.,  
and Eisenman, R. N. (1996). Myc and Max homologs in  
15 *Drosophila*. *Science* 274, 1523-1527.
- Kimura, K. D., Tissenbaum, H. A., Liu, Y., and Ruvkun, G.  
(1997). *daf-2*, an insulin receptor-like gene that  
regulates longevity and diapause in *Caenorhabditis*  
20 *elegans*. *Science* 277, 942-946.
- Leevers, S. J., Weinkove, D., MacDougall, L. K., Hafen,  
E., and Waterfield, M. D. (1996). The *Drosophila*  
phosphoinositide 3-kinase Dp110 promotes cell growth.  
25 *EMBO J.* 15, 6584-6594.
- Minari, O. and Zliversmit, D. B. (1963). Use of KCN for  
stabilization of color in direct Nesslerization of  
Kjeldahl digests. *Anal. Biochem.* 6, 320-327.  
30
- Morata, G. and Ripoll, P. (1975). Minutes: Mutants of  
*Drosophila* autonomously affecting cell division rate.  
*Dev. Biol.* 42, 211-221.
- 35 Neufeld, T. P., Delacruz, A. F. A., Johnston, L. A., and  
Edgar, B. A. (1998). Coordination of Growth and Cell  
Division in the *Drosophila* Wing. *Cell* 93, 1183-1193.
- Olivier, J. P., Raabe, T., Henkemeyer, M., Dickson, B.,  
40 Mbamalu, G., Margolis, B., Schlessinger, J., Hafen, E.,  
and Pawson, T. (1993). A *Drosophila* SH2-SH3 adaptor  
protein implicated in coupling the sevenless tyrosine  
kinase to an activator of Ras guanine nucleotide  
exchange, Sos. *Cell* 73, 179-191.  
45
- Quiring, R., Walldorf, U., Kloter, U., and Gehring, W. J.  
(1994). Homology of the *eyeless* gene of *Drosophila* to the  
Small eye gene in mice and Aniridia in humans. *Science*  
265, 785-789.  
50

- Riddle, D. L. (1988). The dauer larva. In *The nematode Caenorhabditis elegans*, W. N. Wood, ed. (Cold Spring Harbor: Cold Spring Harbor Laboratory Press) 393-412.
- 5 Riesgo-Escovar, J. R., Jenni, M., Fritz, A., and Hafen, E. (1996). The *Drosophila* Jun-N-terminal kinase is required for cell morphogenesis but not for DJun-dependent cell fate specification in the eye. *Genes Dev.* 10, 2759-2768.
- 10 Robertson, F. W. (1963). The ecological genetics of growth in *Drosophila*. VI. The genetic correlation between the duration of the larval period and body size in relation to larval diet. 4, 74-92.
- 15 Santamaria, P. (1983). Analysis of haploid mosaics in *Drosophila*. *Dev. Biol.* 96, 285-295.
- 20 Simpson, P. (1979). Parameters of cell competition in the compartments of the wing disc of *Drosophila*. *Dev. Biol.* 69, 182-193.
- 25 Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W. G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R. J., Neel, B. G., Birge, R. B., Fajardo, J. E., Chou, M. M., Hanafusa, H., Schaffhausen, B., and Cantley, L. C. (1993). SH2 domains recognize specific phosphopeptide sequences. *Cell* 72, 767-778.
- 30 Staveley, B. E., Ruel, L., Jin, J., Stambolic, V., Mastronardi, F. G., Heitzler, P., Woodgett, J. R., and Manoukian, A. S. (1998). Genetic analysis of protein kinase B (AKT) in *Drosophila*. *Curr. Biol.* 8, 599-602.
- 35 Stewart, C. E. and Rotwein, P. (1996). Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. *Physiological Reviews* 76, 1005-1026.
- 40 Thomas, G. and Hall, M. N. (1997). TOR signalling and control of cell growth. *Curr. Opin. Cell Biol.* 9, 782-787.
- 45 van Handel, E. and Day, J. F. (1988). Assay of lipids, glycogen and sugars in individual mosquitoes: correlations with wing length in field-collected *Aedes vexans*. *J. Amer. Mosq. Contr. Assoc.* 4, 549-550.

- 5 Weigmann, K., Cohen, S. M., and Lehner, C. F. (1997).  
Cell cycle progression, growth and patterning in imaginal  
discs despite inhibition of cell division after  
inactivation of *Drosophila* Cdc2 kinase. *Development* 124,  
3555-3563.
- 10 Weinkove, D., Leever, S. J., MacDougall, L. K., and  
Waterfield, M. D. (1997). p60 is an adaptor for the  
*Drosophila* phosphoinositide 3-kinase, Dp110. *J. Biol.*  
*Chem.* 272, 14606-14610.
- 15 Xu, T. and Rubin, G. M. (1993). Analysis of genetic  
mosaics in developing and adult *Drosophila* tissues.  
*Development* 117, 1223-1237.
- 20 Yenush, L., Fernandez, R., Myers, M. G., Jr., Grammer, T.  
C., Sun, X. J., Blenis, J., Pierce, J. H., Schlessinger,  
J., and White, M. F. (1996). The *Drosophila* insulin  
receptor activates multiple signaling pathways but  
requires insulin receptor substrate proteins for DNA  
synthesis. *Mol. Cell. Biol.* 16, 2509-2517.
- 25 Yenush, L. and White, M. F. (1997). The IRS-signalling  
system during insulin and cytokine action. *Bioessays* 19,  
491-500.

10/019098

531 Rec'd PCT/.. 20 DEC 2001

Claims

1. A method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable chico mutant insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size and/or cell size and/or development time and/or lipid level is determined whereby alterations of the body size and/or cell size and/or development time and/or lipid level are detectable in at least part of the animal.

2. The method of claim 1 characterized in that the viable chico mutant insect comprises at most one wild-type *chico* gene.

3. The method of claim 2 wherein the mutant is a *Drosophila* mutant and wherein said mutant is treated in the egg or larvae stadium with said compound or compound generating means.

4. The method of claim 2 or 3 wherein the mutant does not comprise a wild-type *chico* gene.

5. The method of claim 2 or 3 wherein the *Drosophila* mutant comprises one wild-type *chico* gene.

6. The method of claim 5 wherein the wild-type *chico* gene encodes the amino acid sequence of Table 1 (SEQ. ID. NO. 2, 3).

7. The method of claim 6, wherein the wild-type *chico* gene is the genomic or the cDNA sequence represented in Table 1 (SEQ. ID. NO. 1, 2) or Table 2 (SEQ. ID. NO. 4).

8. The method of anyone of claims 2 to 7 wherein the *Drosophila* mutant comprises at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

9. The method of claim 7 wherein the *chico* mutation is the mutation described in Figure 3A.

10. The method of anyone of claims 2 to 9 wherein the *Drosophila* lacks at least one *chico* gene.

11. The method of claim 10 wherein the mutant lacks both *chico* genes.

5 12. The method of anyone of claims 1 to 11 wherein the compound is a compound for the treatment of diabetes type 2.

13. The method of anyone of claims 1 to 12, wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the whole animal.

14. The method of anyone of claims 1 to 12, wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the head region only.

15 15. A viable insect mutant comprising at most one wild-type *chico* gene in at least a part of its body and said at least one part of the body shows reduced size.

20 16. The mutant of claim 15 that does not comprise as sole *chico* genes two *chico*<sup>1</sup> genes.

17. The mutant of claim 15 or 16 that does not comprise a wild-type *chico* gene.

25 18. The mutant of claim 15 or 16 that comprises one wild-type *chico* gene.

19. The mutant of claim 18 wherein the wild-type *chico* gene encodes the amino acid sequence of Table 1 (SEQ. ID. NO. 2, 3).

30 20. The mutant of claim 19, wherein the wild-type *chico* gene is the genomic or the cDNA sequence represented in Table 2 (SEQ. ID. NO. 4) or Table 1 (SEQ. ID. NO. 1, 2).

21. The mutant of anyone of claims 15 to 20 comprising at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

22. The mutant of claim 21 wherein the *chico* mutation is the mutation described in Figure 3A.

23. The mutant of anyone of claims 15 to 22 lacking at least one *chico* gene.

24. The mutant of claim 15 lacking both *chico* genes.

5 25. The mutant of anyone of claims 15 to 24 which is a fly mutant, in particular a *Drosophila* mutant.

26. The mutant of anyone of claims 15 to 25, wherein at most one wild-type *chico* gene is found in the whole body of the insect.

10 27. The mutant of anyone of claims 15 to 25, wherein at most one wild-type *chico* gene is found in the head region of the insect only.

28. Use of an insect according to anyone of claims 15 to 27 as a means in screening compounds for  
15 modulating diseases.

29. Use of an insect according to anyone of claims 15 to 27 as a means for searching for mutations involved directly or indirectly in the insulin signaling pathway.

20 30. Use according to claim 22 or 23, characterized in that the disease is diabetes type 2.

31. A method for generating a mutant insect, characterized in that adult animals, in particular males, are treated with a mutation generating means under  
25 mutation generating conditions, that thus treated insects are crossed to wild-type or mutant insects, in particular *chico* mutant insects, and that viable offsprings with altered cell number and /or cell size and/or developmental time and/or lipid levels are cultivated  
30 under suitable conditions.






Figure 1A




Figure 1B




Figure 2A




Figure 2B




Figure 2C






Figure 3A

MASISDDGMALSGYLKKLKTMMKKFFVLYEETSTSAARLEYDYDTEKKFLQRAEPKRVLYLKNCFN  
 INRRLDTKHREVIIVLSSRDGGEGIVLENENDLRKWLDKLLVLQRNIANSNGTAHSPYDHWQVVI  
 QKKGISEKVGITGYHCCLTSSKSLTFVCIPEKTPNGEDRVASIEILLTTIRRCGHASPOCIFYV  
 ELGRQSVLGSGLWME.TDNAAIAATNMHNTILSAMS AKTESNTNLINVYQNRPDLSHEPMRKRSS  
 ANEASKPINVNVIONSONSLELRSCSSPHNYGFRERCDSLPTRNGTLSESSNQTYFGSNHGLRS  
 NTISGIRPHSTNKHNSPTFTMPLRCSESEESSISVDESDDNGSFHYRLNTRSETAIPFENID  
 DFASAELEFSKVTEQNVSDENYIPMNPVNPTDAIHEKEKADMQRLEDASLHFNFEHASEKLAKEF  
 DLDSDNQCCRPIRAYSIGNKVEHLKFNKRLGHLNDTGQNPNRVRAYSVGSKSKI PRCDLQRVVLV  
 EDNKHEFTANRSQSSI TKEGTSYGSSANRQKSTSAFLSLKNQINSDRMSDLMEIDFSQATNLE  
 KQFIKNEIPKYIENVFPKAPRTDSSSLTLHATSQKDI FNGTKLNNTAITSEDCYLEMKPVGNG  
 YTPSSNCLPMKVERLKLSDYQTAPPI TATAAPVHDLN KISTYNI SAEKWREQPSRSEEKKSNSPL  
 NDNTFGLKPTNVESTSKSHDVHSANQIDSEKVCASQSSDKLNNLADKI VENNNLDIGGHEEKKLVH  
 SISSEDTQIKDKSNDFTKFNEAGYKILQIKSDSSLISSKLYQKGIHKDNLERSQRLTESVNTIP  
 DNATATAVSSSLTKFNINSAPAAAADSRSTGTDPTPQNILQIKDLNFPSSSSRISQPELHY  
 ASLDLPHCSGQNPAYLKRGSRESPPVSACPEDGNTYAKIDFDQSDSSSSSNIFNTZ

**Figure 3B**

CHICOPH	1	.....	MALSGY LK LK LK T	.....	MK K K F F V L	.....	Y E E T S T S A A R L E Y Y
IRS1PH	1	M A S P P D T D G F S D	V R K V G Y L R K P K S	.....	M H K R F F V L R A	.....	P A R L E Y Y
IRS2PH	1	.....	S V R K C G Y L R K Q K H	.....	G H K R F F V L R G P G T G G D E A S A A G S P P Q P P R L E Y Y	.....	P A R L E Y Y
IRS3PH	1	.....	D V R L C G H L R K Q K S	Q F T R R R F F V L R A	.....	.....	D P P R L E Y Y
IRS4PH	1	.....	E V C K R G Y L R K Q K H	.....	G H R R F F V L K L	.....	E T A D A P A R L E Y Y
consensus			V i k G Y L R K Q K T	.....	h k r f f v l r	.....	p a r l e y y
CHICOPH	35	D T E K K F L Q R A	.....	.....	D S K R V I Y L K N C F N I N R R L D T K H R F V I V L S	.....	.....
IRS1PH	48	E N E K K W	.....	.....	P K R S I P L E S C F N I N K R A D S K N K H L V A L	.....	.....
IRS2PH	48	E S E K K W	.....	.....	P K R V I A L D C C L N I N K R A D A K E K Y L I A L	.....	.....
IRS3PH	34	E S E K K F L A S G C R P P R	.....	.....	P R R T V S L E G A C T I S K R A D A R Y Q R H L I V I F T	.....	.....
IRS4PH	36	E N A R K F R H S V R A A A A A A A A S G A A I P P L I P P R R V I T L Y Q C F S V S Q R A D A R Y R H L I A L	.....	.....	p k r v i l e c i n i n R a d a k r h l i a l	.....	.....
consensus		e e k k i	a	.....	.....	.....	.....
CHICOPH	74	. S R D G G F G I V L E N E N D L R K M L D K L L V	.....	.....	.....	.....	.....
IRS1PH	87	Y T R D E H F A I A A D S E A E Q D S W Y Q A L L Q L H N R	.....	.....	.....	.....	.....
IRS2PH	87	Y T K D E Y F A V A A E N E Q E Q E G W Y R A L T D L	.....	.....	.....	.....	.....
IRS3PH	78	Y T S D S S L G V A A A S E A E Q Q T W Y S A L L E V	.....	.....	.....	.....	.....
IRS4PH	94	F T Q D E Y F A M V A E N E S E Q E S W Y L L L S R E	.....	.....	.....	.....	.....
consensus		y t d e f a a e n e e q w y a l l	.....	.....	.....	.....	.....
CHICOPH	1	. D H V W	.....	.....	.....	.....	.....
IRS1PH	1	F K E V M	.....	.....	.....	.....	.....
IRS2PH	1	V R E V M	.....	.....	.....	.....	.....
IRS3PH	1	F Q D V W F T P V T L R S K G L G R A P G L S S G S Y R L C L S G A L S L L R K P G S K G S R D S R A T P P P V L R L	.....	.....	.....	.....	.....
IRS4PH	1	Y K D V W	.....	.....	.....	.....	.....
consensus		V w q v v l k p k g i g k i g y r i c l t s i v i n e s	.....	.....	.....	.....	.....
CHICOPH	53	L T T I R R C G H A S P Q C I F Y V E L G R Q S V L G S G D L W M E T D N A A I A T N M H N T I L S A M	.....	.....	.....	.....	.....
IRS1PH	48	Q L M N I R R C G H S	.....	.....	.....	.....	.....
IRS2PH	61	Q L M N I R R C G H S	.....	.....	.....	.....	.....
IRS3PH	48	S L L S V R R C G H A	.....	.....	.....	.....	.....
IRS4PH	48	Q L L S I R R C G H S	.....	.....	.....	.....	.....
consensus		q l l i r r c g h s f f i e v g r s a v g p g e l w m q d d v v a q n m h e t i l e a m r a l	.....	.....	.....	.....	.....

Figure 3C

**Figure 4A****Figure 4B****Figure 4C**

8/9




Figure 5A






Figure 5B

## DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "IN VIVO INSECT MODEL SYSTEM FOR TYPE-2 DIABETES," the specification of which (check one): ☐ is attached hereto; ☒ was filed on December 20, 2001 as Application Serial No. 10/019,098; ☒ was filed as PCT International Application No. PCT/IB99/01166 on June 22, 1999. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

			Priority Claimed	
(Application Serial Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below:

(Application Serial Number)	(Day/Month/Year Filed)
(Application Serial Number)	(Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PCT/IB99/01166	June 22, 1999	Pending
(Application Serial Number)	(Day/Month/Year Filed)	(Status-Patented, Pending or Abandoned)
(Application Serial Number)	(Day/Month/Year Filed)	(Status-Patented, Pending or Abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

## APPLICABLE RULES AND STATUTES

### 37 CFR 1.56. DUTY OF DISCLOSURE - INFORMATION MATERIAL TO PATENTABILITY (Applicable Portion)

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentability defines, to make sure that any material information contained therein is disclosed to the Office.

Information relating to the following factual situations enumerated in 35 USC 102 and 103 may be considered material under 37 CFR 1.56(a).

### 35 U.S.C. 102. CONDITIONS FOR PATENTABILITY: NOVELTY AND LOSS OF RIGHT TO PATENT

A person shall be entitled to a patent unless --

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent, or
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or
- (c) he has abandoned the invention, or
- (d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months before the filing of the application in the United States, or
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraph (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent, or
- (f) he did not himself invent the subject matter sought to be patented, or
- (g) before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.

### 35 U.S.C. 103. CONDITIONS FOR PATENTABILITY; NON-OBVIOUS SUBJECT MATTER (Applicable Portion)

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

### 35 U.S.C. 112. SPECIFICATION (Applicable Portion)

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

POWER OF ATTORNEY: I hereby appoint as my attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

John B. Lungmus(18,566)  
Allen H. Gerstein (22,218)  
Nate F. Scarpelli (22,320)  
Michael F. Borun (25,447)  
Carl E. Moore, Jr. (26,487)  
Richard H. Anderson (26,526)  
Patrick D. Ertel (26,877)


Richard B. Hoffman(26,910)  
James P. Zeller (28,491)  
Kevin D. Hogg (31,839)  
Jeffrey S. Sharp (31,879)  
Martin J. Hirsch (32,237)  
Richard M. La Barge (32,254)  
James J. Napoli (32,361)

Robert M. Gerstein (34,824)  
Michael R. Hull (35,902)  
Anthony G. Sitko (36,278)  
James A. Flight (37,622)  
Roger A. Heppermann (37,641)  
David A. Gass (38,153)  
Gregory C. Mayer (38,238)

Michael R. Weiner (38,359)  
David C. Read (39,811)  
Thomas A. Miller (40,091)  
William K. Merkel (40,725)  
Sandip H. Patel (43,848)  
Kevin M. Flowers (44,684)  
William J. Kramer (46,229)

Send correspondence to: Jeffrey S. Sharp

FIRM NAME	PHONE NO.	STREET	CITY & STATE	ZIP CODE
<u>Marshall, Gerstein &amp; Borun</u>	<u>312-474-6300</u>	<u>6300 Sears Tower</u> <u>233 South Wacker Drive</u>	<u>Chicago, Illinois</u>	<u>60606-6357</u>

Full Name of First or Sole Inventor <u>Ernst Hafen</u>	Citizenship <u>Swiss</u>
Residence Address - Street <u>Zoologisches Institut/Winterthurerstrasse 190</u>	Post Office Address - Street <u>Zoologisches Institut/Winterthurerstrasse 190</u>
City (Zip) <u>CH-8057 Zürich CHX</u>	City (Zip) <u>CH-8057 Zürich</u>
State or Country <u>Switzerland</u>	State or Country <u>Switzerland</u>
Date <input checked="" type="checkbox"/> <u>13.03.02</u>	Signature <input checked="" type="checkbox"/> 

## SEQUENCE LISTING

<110> Universitaet Zuerich

<120> In vivo model system for type-2 diabetes

<130> Universitaet Zuerich

<140>

<141>

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 2907

<212> DNA

<213> Dosophila melanogaster

<400> 1

atggcatcaa tatcggatga cggcatggcg ctgagtggct acctcaagaa gctgaagacc 60  
atgaagaaga agttctttgt gctgtacgag gagacgagca cttcggcagc cgggctggag 120  
tactacgata ccgaaaagaa gttcctgcaa agagccgagc caaaaagggt tatatatctg 180  
aagaattgct tcaacatcaa tcgccgtttg gacaccaagc atagatttgt cattgtgctc 240  
tcctccagag acggtggatt cggcatcggt ctcgagaacg aaaatgattt acgcaaatgg 300  
ttggacaaac tactagttct acaaaggaac atagccaatt cgaatggaac agcgactca 360  
ccttatgacc acgtttggca agttgtcatt caaaagaagg gtatttcgga gaaagttgga 420  
atcaccggaa cctaccactg ttgccttact tcaaaatccc tgacattcgt gtgcattgga 480  
ccggagaaga cgcccaatgg cgaggatcgc gttgcgagca ttgaaatact tttgaccacg 540  
atcaggcgat gcggtcatgc atccccacaa tgtatattct acgtggaact tggccgcaa 600  
agtgtcttgg gatctggtga tctgtggatg gagacggata acgcagctat tgctactaat 660  
atgcacaaca cgatactgag cgctatgtca gccaaaacag agtcgaacac gaatttaata 720  
aacgtttatc agaatagacc tgacttaagt caccagccca tgagaaagcg atcgtcgtct 780  
gcaaacgaag catcgaagcc gataaacgta aatgtcatatc aaaatagtc aaactctctc 840

gaattgcgca gctgcagttc gccccataac tatggtttcg gcagagagag atgcgatagc 900  
ttaccaacca gaaatggaac cctaagcgag tccagcaatc aaacgtactt tggttccaac 960  
catggactgc gatccaatac tataatctggc atccgtccgc actcaaccaa caagcatagt 1020  
aatagtccaa cgttcaccat gccattaaga tgctcagaat ccgaagagtc atcaattagt 1080  
gtcgatgaat ccgacgacaa cggcagtttt agccactaca gattaaacac gcggtcatct 1140  
gagacggcaa ttcttgagga aaacattgat gactttgcca gtgcggaatt atttagcaaa 1200  
gtcaccgaac aaaatgtaag tgacgaaaac tacataccga tgaatccagt caatcctacc 1260  
gatgctatcc atgaaaagga gaaggctgat atgcagagat tggaagatgc ttcgctgcat 1320  
ttcaactttc cggagcacgc gtcggaaaag cttgctaagg attttgatct ggactctgat 1380  
aaccaatgct gtctgcccac tcgcgcctat tcgataggca acaagggtga gcatttaaag 1440  
tttaataagc gcctgggaca cttgaatgat acgggacaga atccgaatcg cgtgcgagcc 1500  
tactcggttg gtcctaaatc gaagataccg cgctgcgacc tgcagcgagt ggtcctcgtg 1560  
gaggacaata aacatgagtt cacagcgaat aggagtcaga gtagcattac caaggaagga 1620  
accagctatg gcagcagtgc caatcgacaa aagaagtcca caagtgtcc actcctcagt 1680  
ctgaagaacc agataaaactc cgaccgaatg agtgacttaa tggaattga tttttcacia 1740  
gcaaccaatt tggaaaagca gaagttcatc aagaataatg aaattccgaa atacattgaa 1800  
aacgtgttcc caaaagcccc gcgaacggat agctccagcc taactctgca cgccacaagt 1860  
caaaaggaca ttttcaatgg caccaaacta aataaactg cgatcacatc cgaggatggt 1920  
tacctcgaga tgaagccagt cggtaatgga tacactocca gttcgaattg cctgccaatg 1980  
aaagtggaga aactcaagct atccgactat cagacagcac cgccactcac cgcaacagcc 2040  
gcaccagtgc acgatttaaa caaaattagc acatacaata tatccgctga gaaatggaga 2100  
gaacagccca gcagaagcga ggaaaagaag tcgaactcgc cattgaatga caacaccttt 2160  
agctcgaaac ccacaaatgt cgagagtaca agcaaaagcc atgatgttca ttcagcaaat 2220  
caaattgatt gcgagaaagt gtgcgcgcag agcagcgata agctaaataa tcctctggcc 2280

gacaagattg tcgagaacaa caatttggat ataggcgggc atgaggaaaa gaagttggtt 2340  
cattcgataa gcagcgaaga ctacacacaa atcaaggaca aatcgaatga tttcacaaaa 2400  
ttaaacgaag ccggctacaa aattctgcaa attaaaagcg acagctcact catctcatcg 2460  
aagctatacc aaaaggtat acacaaggat aacttggagc gttcgcagag acttacagag 2520  
agtggtgaata cgattcccga taatgccacc gccaccgcgg tgagcagcag ctcaactcacc 2580  
aaattcaata taaattcagc aaagccagcc gccgccgccg attcgcgtag cactggcaca 2640  
gatccaagta caccacagaa cattctacag attaaagatt tgaatttccc ctcaagggtcg 2700  
tcgtctcgca tatcccagcc ggagctgcac tacgccagcc tagatcttcc ccattgcagt 2760  
ggccaaaatc cagctaaata cctgaagaga ggatcacgcg aatcgccgcc ggtgtccgca 2820  
tgcccggagg atgggaatac ctatgcgaaa atcgactttg accaatccga ctctcttccc 2880  
tcctcatcga acatatttaa tacgtaa 2907

&lt;210&gt; 2

&lt;211&gt; 2907

&lt;212&gt; DNA

<213> *Drosophila melanogaster*

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(2907)

&lt;400&gt; 2

atg gca tca ata tcg gat gac ggc atg gcg ctg agt ggc tac ctc aag 48  
Met Ala Ser Ile Ser Asp Asp Gly Met Ala Leu Ser Gly Tyr Leu Lys

1

5

10

15

aag ctg aag acc atg aag aag aag ttc ttt gtg ctg tac gag gag acg 96  
Lys Leu Lys Thr Met Lys Lys Lys Phe Phe Val Leu Tyr Glu Glu Thr

20

25

30

agc act tcg gca gcc cgg ctg gag tac tac gat acc gaa aag aag ttc 144  
Ser Thr Ser Ala Ala Arg Leu Glu Tyr Tyr Asp Thr Glu Lys Lys Phe

35

40

45

ctg caa aga gcc gag cca aaa agg gtt ata tat ctg aag aat tgc ttc 192  
Leu Gln Arg Ala Glu Pro Lys Arg Val Ile Tyr Leu Lys Asn Cys Phe

60

aac gtt tat cag aat aga cct gac tta agt cac gag ccc atg aga aag 768  
Asn Val Tyr Gln Asn Arg Pro Asp Leu Ser His Glu Pro Met Arg Lys



245	250	255	
cga tcg tcg tct gca aac gaa gca tcg aag ccg ata aac gta aat gtc			816
Arg Ser Ser Ser Ala Asn Glu Ala Ser Lys Pro Ile Asn Val Asn Val			
260	265	270	
ata caa aat agt caa aac tct ctc gaa ttg cgc agc tgc agt tcg ccc			864
Ile Gln Asn Ser Gln Asn Ser Leu Glu Leu Arg Ser Cys Ser Ser Pro			
275	280	285	
cat aac tat ggt ttc ggc aga gag aga tgc gat agc tta cca acc aga			912
His Asn Tyr Gly Phe Gly Arg Glu Arg Cys Asp Ser Leu Pro Thr Arg			
290	295	300	
aat gga acc cta agc gag tcc agc aat caa acg tac ttt ggt tcc aac			960
Asn Gly Thr Leu Ser Glu Ser Ser Asn Gln Thr Tyr Phe Gly Ser Asn			
305	310	315	320
cat gga ctg cga tcc aat act ata tct ggc atc cgt ccg cac tca acc			1008
His Gly Leu Arg Ser Asn Thr Ile Ser Gly Ile Arg Pro His Ser Thr			
325	330	335	
aac aag cat agt aat agt cca acg ttc acc atg cca tta aga tgc tca			1056
Asn Lys His Ser Asn Ser Pro Thr Phe Thr Met Pro Leu Arg Cys Ser			
340	345	350	
gaa tcc gaa gag tca tca att agt gtc gat gaa tcc gac gac aac ggc			1104
Glu Ser Glu Glu Ser Ser Ile Ser Val Asp Glu Ser Asp Asp Asn Gly			
355	360	365	
agt ttt agc cac tac aga tta aac acg cgg tca tct gag acg gca att			1152
Ser Phe Ser His Tyr Arg Leu Asn Thr Arg Ser Ser Glu Thr Ala Ile			
370	375	380	
cct gag gaa aac att gat gac ttt gcc agt gcg gaa tta ttt agc aaa			1200
Pro Glu Glu Asn Ile Asp Asp Phe Ala Ser Ala Glu Leu Phe Ser Lys			
385	390	395	400
gtc acc gaa caa aat gta agt gac gaa aac tac ata ccg atg aat cca			1248
Val Thr Glu Gln Asn Val Ser Asp Glu Asn Tyr Ile Pro Met Asn Pro			
405	410	415	
gtc aat cct acc gat gct atc cat gaa aag gag aag gct gat atg cag			1296
Val Asn Pro Thr Asp Ala Ile His Glu Lys Glu Lys Ala Asp Met Gln			
420	425	430	
aga ttg gaa gat gct tcg ctg cat ttc aac ttt ccg gag cac gcg tcg			1344
Arg Leu Glu Asp Ala Ser Leu His Phe Asn Phe Pro Glu His Ala Ser			

435	440	445	
gaa aag ctt gct aag gat ttt gat ctg gac tct gat aac caa tgc tgt			1392
Glu Lys Leu Ala Lys Asp Phe Asp Leu Asp Ser Asp Asn Gln Cys Cys			
450	455	460	
cg t ccc att cgc gcc tat tcg ata ggc aac aag gtt gag cat tta aag			1440
Arg Pro Ile Arg Ala Tyr Ser Ile Gly Asn Lys Val Glu His Leu Lys			
465	470	475	480
ttt aat aag cgc ctg gga cac ttg aat gat acg gga cag aat ccg aat			1488
Phe Asn Lys Arg Leu Gly His Leu Asn Asp Thr Gly Gln Asn Pro Asn			
485	490	495	
cg c gtg cga gcc tac tcg gtt ggc tcc aaa tcg aag ata ccg cgc tgc			1536
Arg Val Arg Ala Tyr Ser Val Gly Ser Lys Ser Lys Ile Pro Arg Cys			
500	505	510	
gac ctg cag cga gtg gtc ctc gtg gag gac aat aaa cat gag ttc aca			1584
Asp Leu Gln Arg Val Val Leu Val Glu Asp Asn Lys His Glu Phe Thr			
515	520	525	
gcg aat agg agt cag agt agc att acc aag gaa gga acc agc tat ggc			1632
Ala Asn Arg Ser Gln Ser Ser Ile Thr Lys Glu Gly Thr Ser Tyr Gly			
530	535	540	
agc agt gcc aat cga caa aag aag tcc aca agt gct cca ctc ctc agt			1680
Ser Ser Ala Asn Arg Gln Lys Lys Ser Thr Ser Ala Pro Leu Leu Ser			
545	550	555	560
ctg aag aac cag ata aac tcc gac cga atg agt gac tta atg gaa att			1728
Leu Lys Asn Gln Ile Asn Ser Asp Arg Met Ser Asp Leu Met Glu Ile			
565	570	575	
gat ttt tca caa gca acc aat ttg gaa aag cag aag ttc atc aag aat			1776
Asp Phe Ser Gln Ala Thr Asn Leu Glu Lys Gln Lys Phe Ile Lys Asn			
580	585	590	
aat gaa att ccg aaa tac att gaa aac gtg ttc cca aaa gcc ccg cga			1824
Asn Glu Ile Pro Lys Tyr Ile Glu Asn Val Phe Pro Lys Ala Pro Arg			
595	600	605	
acg gat agc tcc agc cta act ctg cac gcc aca agt caa aag gac att			1872
Thr Asp Ser Ser Ser Leu Thr Leu His Ala Thr Ser Gln Lys Asp Ile			
610	615	620	
ttc aat ggc acc aaa cta aat aac act gcg atc aca tcc gag gat ggt			1920
Phe Asn Gly Thr Lys Leu Asn Asn Thr Ala Ile Thr Ser Glu Asp Gly			

625	630	635	640	
tac ctc gag atg aag cca gtc ggt aat gga tac act ccc agt tcg aat				1968
Tyr Leu Glu Met Lys Pro Val Gly Asn Gly Tyr Thr Pro Ser Ser Asn				
645		650	655	
tgc ctg cca atg aaa gtg gag aaa ctc aag cta tcc gac tat cag aca				2016
Cys Leu Pro Met Lys Val Glu Lys Leu Lys Leu Ser Asp Tyr Gln Thr				
660		665	670	
gca ccg cca ctc acc gca aca gcc gca cca gtg cac gat tta aac aaa				2064
Ala Pro Pro Leu Thr Ala Thr Ala Ala Pro Val His Asp Leu Asn Lys				
675		680	685	
att agc aca tac aat ata tcc gct gag aaa tgg aga gaa cag ccc agc				2112
Ile Ser Thr Tyr Asn Ile Ser Ala Glu Lys Trp Arg Glu Gln Pro Ser				
690		695	700	
aga agc gag gaa aag aag tcg aac tcg cca ttg aat gac aac acc ttt				2160
Arg Ser Glu Glu Lys Lys Ser Asn Ser Pro Leu Asn Asp Asn Thr Phe				
705		710	715	720
agc tcg aaa ccc aca aat gtc gag agt aca agc aaa agc cat gat gtt				2208
Ser Ser Lys Pro Thr Asn Val Glu Ser Thr Ser Lys Ser His Asp Val				
725		730	735	
cat tca gca aat caa att gat tgc gag aaa gtg tgc gcg cag agc agc				2256
His Ser Ala Asn Gln Ile Asp Cys Glu Lys Val Cys Ala Gln Ser Ser				
740		745	750	
gat aag cta aat aat cat ctg gcc gac aag att gtc gag aac aac aat				2304
Asp Lys Leu Asn Asn His Leu Ala Asp Lys Ile Val Glu Asn Asn Asn				
755		760	765	
ttg gat ata ggc ggg cat gag gaa aag aag ttg gtt cat tcg ata agc				2352
Leu Asp Ile Gly Gly His Glu Glu Lys Lys Leu Val His Ser Ile Ser				
770		775	780	
agc gaa gac tac aca caa atc aag gac aaa tcg aat gat ttc aca aaa				2400
Ser Glu Asp Tyr Thr Gln Ile Lys Asp Lys Ser Asn Asp Phe Thr Lys				
785		790	795	800
ttt aac gaa gcc ggc tac aaa att ctg caa att aaa agc gac agc tca				2448
Phe Asn Glu Ala Gly Tyr Lys Ile Leu Gln Ile Lys Ser Asp Ser Ser				
805		810	815	
ctc atc tca tcg aag cta tac caa aag ggt ata cac aag gat aac ttg				2496
Leu Ile Ser Ser Lys Leu Tyr Gln Lys Gly Ile His Lys Asp Asn Leu				

	820		825		830	
	gag cgt tcg cag aga ctt aca	gag agt gtg aat acg att ccc gat aat	2544			
	Glu Arg Ser Gln Arg Leu Thr	Glu Ser Val Asn Thr Ile Pro Asp Asn				
	835	840	845			
	gcc acc gcc acc gcg gtg agc agc agc tca ctc acc aaa ttc aat ata	2592				
	Ala Thr Ala Thr Ala Val Ser Ser Ser Ser Leu Thr Lys Phe Asn Ile					
	850	855	860			
	aat tca gca aag cca gcc gcc gcc gcc gat tcg cgt agc act ggc aca	2640				
	Asn Ser Ala Lys Pro Ala Ala Ala Ala Asp Ser Arg Ser Thr Gly Thr					
	865	870	875 880			
	gat cca agt aca cca cag aac att cta cag att aaa gat ttg aat ttc	2688				
	Asp Pro Ser Thr Pro Gln Asn Ile Leu Gln Ile Lys Asp Leu Asn Phe					
	885	890	895			
	ccc tca agg tcg tcg tct cgc ata tcc cag ccg gag ctg cac tac gcc	2736				
	Pro Ser Arg Ser Ser Ser Arg Ile Ser Gln Pro Glu Leu His Tyr Ala					
	900	905	910			
	agc cta gat ctt ccc cat tgc agt ggc caa aat cca gct aaa tac ctg	2784				
	Ser Leu Asp Leu Pro His Cys Ser Gly Gln Asn Pro Ala Lys Tyr Leu					
	915	920	925			
	aag aga gga tca cgc gaa tcg ccg ccg gtg tcc gca tgc ccg gag gat	2832				
	Lys Arg Gly Ser Arg Glu Ser Pro Pro Val Ser Ala Cys Pro Glu Asp					
	930	935	940			
	ggg aat acc tat gcg aaa atc gac ttt gac caa tcc gac tcc tct tcc	2880				
	Gly Asn Thr Tyr Ala Lys Ile Asp Phe Asp Gln Ser Asp Ser Ser Ser					
	945	950	955 960			
	tcc tca tcg aac ata ttt aat acg taa	2907				
	Ser Ser Ser Asn Ile Phe Asn Thr					
	965					

&lt;210&gt; 3

&lt;211&gt; 969

&lt;212&gt; PRT

<213> *Drosophila melanogaster*

&lt;400&gt; 3

Met Ala Ser Ile Ser Asp Asp Gly Met Ala Leu Ser Gly Tyr Leu Lys

1

5

10

15

Lys Leu Lys Thr Met Lys Lys Lys Phe Phe Val Leu Tyr Glu Glu Thr  
 20 25 30  
 Ser Thr Ser Ala Ala Arg Leu Glu Tyr Tyr Asp Thr Glu Lys Lys Phe  
 35 40 45  
 Leu Gln Arg Ala Glu Pro Lys Arg Val Ile Tyr Leu Lys Asn Cys Phe  
 50 55 60  
 Asn Ile Asn Arg Arg Leu Asp Thr Lys His Arg Phe Val Ile Val Leu  
 65 70 75 80  
 Ser Ser Arg Asp Gly Gly Phe Gly Ile Val Leu Glu Asn Glu Asn Asp  
 85 90 95  
 Leu Arg Lys Trp Leu Asp Lys Leu Leu Val Leu Gln Arg Asn Ile Ala  
 100 105 110  
 Asn Ser Asn Gly Thr Ala His Ser Pro Tyr Asp His Val Trp Gln Val  
 115 120 125  
 Val Ile Gln Lys Lys Gly Ile Ser Glu Lys Val Gly Ile Thr Gly Thr  
 130 135 140  
 Tyr His Cys Cys Leu Thr Ser Lys Ser Leu Thr Phe Val Cys Ile Gly  
 145 150 155 160  
 Pro Glu Lys Thr Pro Asn Gly Glu Asp Arg Val Ala Ser Ile Glu Ile  
 165 170 175  
 Leu Leu Thr Thr Ile Arg Arg Cys Gly His Ala Ser Pro Gln Cys Ile  
 180 185 190  
 Phe Tyr Val Glu Leu Gly Arg Gln Ser Val Leu Gly Ser Gly Asp Leu  
 195 200 205  
 Trp Met Glu Thr Asp Asn Ala Ala Ile Ala Thr Asn Met His Asn Thr  
 210 215 220  
 Ile Leu Ser Ala Met Ser Ala Lys Thr Glu Ser Asn Thr Asn Leu Ile  
 225 230 235 240  
 Asn Val Tyr Gln Asn Arg Pro Asp Leu Ser His Glu Pro Met Arg Lys  
 245 250 255  
 Arg Ser Ser Ser Ala Asn Glu Ala Ser Lys Pro Ile Asn Val Asn Val  
 260 265 270

Ile Gln Asn Ser Gln Asn Ser Leu Glu Leu Arg Ser Cys Ser Ser Pro  
 275 280 285

His Asn Tyr Gly Phe Gly Arg Glu Arg Cys Asp Ser Leu Pro Thr Arg  
 290 295 300

Asn Gly Thr Leu Ser Glu Ser Ser Asn Gln Thr Tyr Phe Gly Ser Asn  
 305 310 315 320

His Gly Leu Arg Ser Asn Thr Ile Ser Gly Ile Arg Pro His Ser Thr  
 325 330 335

Asn Lys His Ser Asn Ser Pro Thr Phe Thr Met Pro Leu Arg Cys Ser  
 340 345 350

Glu Ser Glu Glu Ser Ser Ile Ser Val Asp Glu Ser Asp Asp Asn Gly  
 355 360 365

Ser Phe Ser His Tyr Arg Leu Asn Thr Arg Ser Ser Glu Thr Ala Ile  
 370 375 380

Pro Glu Glu Asn Ile Asp Asp Phe Ala Ser Ala Glu Leu Phe Ser Lys  
 385 390 395 400

Val Thr Glu Gln Asn Val Ser Asp Glu Asn Tyr Ile Pro Met Asn Pro  
 405 410 415

Val Asn Pro Thr Asp Ala Ile His Glu Lys Glu Lys Ala Asp Met Gln  
 420 425 430

Arg Leu Glu Asp Ala Ser Leu His Phe Asn Phe Pro Glu His Ala Ser  
 435 440 445

Glu Lys Leu Ala Lys Asp Phe Asp Leu Asp Ser Asp Asn Gln Cys Cys  
 450 455 460

Arg Pro Ile Arg Ala Tyr Ser Ile Gly Asn Lys Val Glu His Leu Lys  
 465 470 475 480

Phe Asn Lys Arg Leu Gly His Leu Asn Asp Thr Gly Gln Asn Pro Asn  
 485 490 495

Arg Val Arg Ala Tyr Ser Val Gly Ser Lys Ser Lys Ile Pro Arg Cys  
 500 505 510

Asp Leu Gln Arg Val Val Leu Val Glu Asp Asn Lys His Glu Phe Thr  
 515 520 525

Ala Asn Arg Ser Gln Ser Ser Ile Thr Lys Glu Gly Thr Ser Tyr Gly  
 530 535 540

Ser Ser Ala Asn Arg Gln Lys Lys Ser Thr Ser Ala Pro Leu Leu Ser  
 545 550 555 560

Leu Lys Asn Gln Ile Asn Ser Asp Arg Met Ser Asp Leu Met Glu Ile  
 565 570 575

Asp Phe Ser Gln Ala Thr Asn Leu Glu Lys Gln Lys Phe Ile Lys Asn  
 580 585 590

Asn Glu Ile Pro Lys Tyr Ile Glu Asn Val Phe Pro Lys Ala Pro Arg  
 595 600 605

Thr Asp Ser Ser Ser Leu Thr Leu His Ala Thr Ser Gln Lys Asp Ile  
 610 615 620

Phe Asn Gly Thr Lys Leu Asn Asn Thr Ala Ile Thr Ser Glu Asp Gly  
 625 630 635 640

Tyr Leu Glu Met Lys Pro Val Gly Asn Gly Tyr Thr Pro Ser Ser Asn  
 645 650 655

Cys Leu Pro Met Lys Val Glu Lys Leu Lys Leu Ser Asp Tyr Gln Thr  
 660 665 670

Ala Pro Pro Leu Thr Ala Thr Ala Ala Pro Val His Asp Leu Asn Lys  
 675 680 685

Ile Ser Thr Tyr Asn Ile Ser Ala Glu Lys Trp Arg Glu Gln Pro Ser  
 690 695 700

Arg Ser Glu Glu Lys Lys Ser Asn Ser Pro Leu Asn Asp Asn Thr Phe  
 705 710 715 720

Ser Ser Lys Pro Thr Asn Val Glu Ser Thr Ser Lys Ser His Asp Val  
 725 730 735

His Ser Ala Asn Gln Ile Asp Cys Glu Lys Val Cys Ala Gln Ser Ser  
 740 745 750

Asp Lys Leu Asn Asn His Leu Ala Asp Lys Ile Val Glu Asn Asn Asn  
 755 760 765

Leu Asp Ile Gly Gly His Glu Glu Lys Lys Leu Val His Ser Ile Ser  
 770 775 780

Ser Glu Asp Tyr Thr Gln Ile Lys Asp Lys Ser Asn Asp Phe Thr Lys  
785 790 795 800

Phe Asn Glu Ala Gly Tyr Lys Ile Leu Gln Ile Lys Ser Asp Ser Ser  
805 810 815

Leu Ile Ser Ser Lys Leu Tyr Gln Lys Gly Ile His Lys Asp Asn Leu  
820 825 830

Glu Arg Ser Gln Arg Leu Thr Glu Ser Val Asn Thr Ile Pro Asp Asn  
835 840 845

Ala Thr Ala Thr Ala Val Ser Ser Ser Ser Leu Thr Lys Phe Asn Ile  
850 855 860

Asn Ser Ala Lys Pro Ala Ala Ala Ala Asp Ser Arg Ser Thr Gly Thr  
865 870 875 880

Asp Pro Ser Thr Pro Gln Asn Ile Leu Gln Ile Lys Asp Leu Asn Phe  
885 890 895

Pro Ser Arg Ser Ser Ser Arg Ile Ser Gln Pro Glu Leu His Tyr Ala  
900 905 910

Ser Leu Asp Leu Pro His Cys Ser Gly Gln Asn Pro Ala Lys Tyr Leu  
915 920 925

Lys Arg Gly Ser Arg Glu Ser Pro Pro Val Ser Ala Cys Pro Glu Asp  
930 935 940

Gly Asn Thr Tyr Ala Lys Ile Asp Phe Asp Gln Ser Asp Ser Ser Ser  
945 950 955 960

Ser Ser Ser Asn Ile Phe Asn Thr  
965

<210> 4

<211> 5210

<212> DNA

<213> *Drosophila melanogaster*

<400> 4

agaacgactt tttcctcctt agtcagtcac aagaaaacta agctttacca acaatacggc 60

gtgtattggtt aaattattac aacaaataaa atattcaaatt tgtattttaaa aatatagttaa 120

ccattaaaaa ataaaatcaa tatgcgaaac tttgtaattt cttactcatc cttgtttttt 180



gagcccgctt tcttaagtta aatcggttaa ataccagttt aatcatttca ttgtcctgat 240  
ttcaggagct aattacattt taatctttgt ataaattcat aaaattaaaa tggaaatggt 300  
taaccacata aaatatattg gtatataaag tcgatacata cttttaaaat tttgtttcat 360  
acaagaatat ggaaagtaga taatttagtt accgattaaa acatttctaa aatacaaaaa 420  
atttaaaatg atgattaaat aaaaaactgt tataactaat ttaaacgaaa caaacggtca 480  
ttcgataact caattagtat cgaataagcc ggcgtgtaaa tcgggttggt aactctcacc 540  
ggtgtagaga tcgggatggc aacttcgtat tgttattcct atgctgcgat aacgataaca 600  
gcaaagtgtc atcggaata aatgtgggtt tgataataaa gaattgcgtt ggtgaacaat 660  
aataatacaa atgctaaatg tatcgcgagg ataactagta aacactgatt tcgcgcatat 720  
cgggcatacg ggcagctaga cgtcttaggt aacacatttc ccagccacat tggcgttgag 780  
gtattatttc ccatatccat gtgcgtttgt aaatgatacc accagagtgt gccatatgta 840  
tcgttgtttg tacatacatg cctacgggga aaaataactc gcagatacat atgtatgtaa 900  
gatgtattag aattccacag atatatgtac atataaatat atatatatat ttatgatgct 960  
catctataaa acaaaatatg tacaacata cgcgcgcacg tacttatgta tgtacatata 1020  
catatataca tatatgtata ataaaatgag catctagctg cggttatctt aatgcaatgc 1080  
gcagaaacct gaaaacgaaa taaacaatct ttacagcgcc agcacagtga gccaattatg 1140  
aattcacaat tccacatcca attccgattc cgaattccat cgctttacat cctaattcga 1200  
atacgtcgcg ccgcgtaagc tgcactcgaa tattgacata aacgacgtaa ttgcgtgttt 1260  
tgattgcgat ttccgatgct cgatgttgac agacggcaag gatttttttt gccagccgac 1320  
attgcgaatg cttttcgcgt gtttgcggtt tgaaaagcga tttgttggtc cggcagttgg 1380  
aatgttttg tgctgtttat gcttagaaaa gcaaatgtat tgcacaaaac tcgtgtttcc 1440  
tacattagta aagcctataa cttaggtata tgtttctaaa ttacaatgca aaaaataaaa 1500  
aacattatac atgtgttcgt tctttaattt gaaaacagaa aagtgaagc cttgcaaatc 1560  
aaatatgtgt ccatatcgcc tactaataat ataaacacgt cgccttcag gaactaagat 1620

tggaaatcat ggcatacaata tcggatgacg gcatggcgct gaggggctac ctcaagaagc 1680  
tgaagaccat gaagaagaag ttctttgtgc tgtacgagga gacgagcact tcggcagccc 1740  
ggctggagta ctacgatacc gaaaagaagt tcctgcaaag agccgagcca aaaaggggta 1800  
tctatctgaa gaattgcttc aacatcaatc gccgtttgga caccaagcat agatttgtca 1860  
ttgtgctctc ctccagagac ggtggattcg gcatcgttct cgagaacgaa aatgatttac 1920  
gcaaattggtt ggacaaacta ctagttctac aaaggaacat agccaattcg aatggaacag 1980  
cgcaactacc ttatggtatg ccaaataaac tataactacc agttagtatg aaacctaac 2040  
acttcatttc actttgcaga ccacgtttgg caagttgtca ttcaaaagaa ggggtatttcg 2100  
gagaaagttg gaatcaccgg aacctaccac tgttgcccta cttcaaaatc cctgacattc 2160  
gtgtgcattg gaccggagaa gacgccaat ggcgaggatc gcgttgcgag cattgaaata 2220  
cttttgacca cgatcaggcg gttagttgtt gccagcaaaa ctgcaaggga ttgtaaaata 2280  
attcggactt aatttcagat gcggtcatgc atccccacaa tgtatattct acgtggaact 2340  
tggccgcaa agtgtcttgg gatctgggta tctgtggatg gagacggata acgcagctat 2400  
tgctactaat atgcacaaca cgatactgag gtatttagct ctattacaa ctaatccaag 2460  
atttcatgat catcctacaa aacgacatag atagttaag atatctccca gtttaacttta 2520  
ataattctgt ggggttttttc tttcagcgct atgtcagcca aaacagagtc gaacacgaat 2580  
ttaataaacg tttatcagaa cagacctgac ttaagtcacg agcccatgag aaagcgatcg 2640  
tcgtctgcaa acgaagcatc gaagccgata aacgtaaatg tcatacaaaa tagtcaaaac 2700  
tctctcgaat tgccgagctg cagttcgccc cataactatg gtaaatactt caaatgtatg 2760  
tttaaagca aaattaatca aacgcaatcg tttcaggtt cgccagagag agatgcgata 2820  
gcttaccac cagaaatgga accctaagcg agtcagcaa tcaaagctac tttgggtcca 2880  
accatggact gcatccaat actatatctg gcatccgtcc gcaactcaacc aacaagcata 2940  
gtaatagtcc aacgttcacc atgccattaa gatgctcaga atccgaagag tcatcaatta 3000  
gtgtcgatga atccgacgac aacggcagtt ttagccacta cagattaaag tgcgttgcta 3060

tcaaataata attattttaat aataatcacc atttcaattt ctagcacgcg gtcactctgag 3120  
acggcaattc ctgaggaaaa cattgatgac tttgccagtg cggaattatt tagcaaagtc 3180  
accgaacaaa atggtaagcc aaacacaaaa acaatttttt aacatgaaaa gtagctaadc 3240  
aattggcttt gtttaactgc agtaagtgc gaaaactaca taccgatgaa tccagtcaat 3300  
cctaccgatg ctatccatga aaaggagaag gctgatatgc agagattgga agatgcttcg 3360  
ctgcatttca actttccgga gcacgcgtcg gaaaagcttg ctaaggattt tgatctggac 3420  
tctgataacc agtgagtaca catttcgctt caactgtgcc acgtaatgca atcaatcaca 3480  
tcttgttaca gatgctgtcg tccatttcgc gcctattcga taggcaacaa ggttgagcat 3540  
ttaagttta ataagcgctt gggacacttg aatgatacgg gacagaatcc gaatcgctg 3600  
cgagcctact cggttggctc caaatcgaag ataccgcgtc gcgacctgca gcgagtggc 3660  
ctcgtggagg acaataaaca tgagttcaca gcgaatagga gtcagagtag cattaccaag 3720  
gaaggaacca gctatggcag cagtgcgaat cgacaaaaga agtcacaaag tgctccactc 3780  
ctcagtctga agaaccagat aaactccgac cgaatgagtg acttaatgga aattgatttt 3840  
tcacaagcaa ccaatttga aaagcagaag ttcataaga ataataaat tccgaaatac 3900  
attgaaaacg tgttcccaaa agccccgcga acggatagct ccagcctaac tctgcacgcc 3960  
acaagtcaaa aggacatttt caatggcacc aaactaaata aactgogat cacatccgag 4020  
gatggttacc tcgagatgaa gccagtcggt aatggataga ctcccagttc gaattgcctg 4080  
ccaatgaaag tggagaggct caagctatcc gactatcaga cagcaccgcc aatcaccgca 4140  
acagccgcac cagtgcacga tttaaacaaa attagcacat acaatatatc cgctgagaaa 4200  
tggagagaac agcccagcag aagcgaggaa aagaagtcga actcgccatt gaatgacaac 4260  
acctttggct tgaaaccac aaatgtcgag agtacaagca aaagccatga tgttcattca 4320  
gcaaatcaaa ttgattccga gaaagtgtgc gcgcagagca gcgataagct aaataatctg 4380  
gccgacaaga ttgtcgagaa caacaatttg gatataggcg ggcagtagga aaagaagttg 4440  
gttcattcga taagcagcga agactacaca caaatcaagg acaaatcgaa tgatttcaca 4500

aaattttaacg aagccggcta caaaattctg caaattaaaa gcgacagctc actcatctca 4560  
tcgaagctat accaaaaggg tatacacaag gataacttgg agcgttcgca gagacttacg 4620  
gagagtgtga atacgattcc cgataatgcc accgccaccg cggtgagcag cagctcactc 4680  
accaaattca atataaattc agcaaagcca gccgccgccg ccgattcgcg tagcactggc 4740  
acagatccaa gtacaccaca gaacattcta cagattaaag atttgaattt cccctcaagg 4800  
tcgtcgtctc gcatatccca gccggagctg cactacgcca gcctagatct tccccattgc 4860  
agtggccaaa atccagctaa atacctgaag agaggatcac gcgaatcgcc gccggtgtcc 4920  
gcatgcccgg aggatgggaa tacctatgcg aaaatcgact ttgaccaatc cgactcctct 4980  
tcctcctcat cgaacatatt taatacgtaa agttttgaaa tttatgacct taccctatat 5040  
atatgatttg tttaatatg tacatttatt gtaaattatt tctgacaagc aaagcttaca 5100  
atattggatg ctaataaata aattttattt aaattataat gatccctttg gacttttttt 5160  
ttttttggac taagaaatca ctactaaaga agggcttttc gagggttaaa 5210